Arfin, Saniya; Jha, Niraj Kumar; Jha, Saurabh Kumar; Kesari, Kavindra Kumar; Ruokolainen, Janne; Roychoudhury, Shubhadeep; Rathi, Brijesh; Kumar, Dhruv

Oxidative stress in cancer cell metabolism

Published in:
Antioxidants

DOI:
10.3390/antiox10050642

Published: 01/05/2021

Published under the following license:
CC BY

Please cite the original version:
Arfin, S., Jha, N. K., Jha, S. K., Kesari, K. K., Ruokolainen, J., Roychoudhury, S., Rathi, B., & Kumar, D. (2021). Oxidative stress in cancer cell metabolism. Antioxidants, 10(5), [642]. https://doi.org/10.3390/antiox10050642
Oxidative Stress in Cancer Cell Metabolism

Saniya Arfin 1, Niraj Kumar Jha 2, Saurabh Kumar Jha 2, Kavindra Kumar Kesari 3, Janne Ruokolainen 3, Shubhadeep Roychoudhury 4, Brijesh Rathi 5 and Dhruv Kumar 1,*

1 Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh, Sec 125, Noida 201303, India; saniya.arfin@amity.edu
2 Department of Biotechnology, School of Engineering & Technology (S.E.T), Sharda University, Greater Noida 201310, India; niraj.jha@sharda.ac.in (N.K.J.); saurabh.jha@sharda.ac.in (S.K.J.)
3 Department of Applied Physics, School of Science, Aalto University, 00076 Espoo, Finland; kavindra.kesari@aalto.fi (K.K.K.); janne.ruokolainen@aalto.fi (J.R.)
4 Department of Life Science and Bioinformatics, Assam University, Silchar 788011, India; shubhadeep1@gmail.com
5 Laboratory for Translational Chemistry and Drug Discovery, Department of Chemistry, Hansraj College, University of Delhi, New Delhi 110021, India; brijeshrathi@hrc.du.ac.in
* Correspondence: dkumar13@amity.edu; Tel.: +91-7082436598

Abstract: Reactive oxygen species (ROS) are important in regulating normal cellular processes whereas deregulated ROS leads to the development of a diseased state in humans including cancers. Several studies have been found to be marked with increased ROS production which activates pro-tumorigenic signaling, enhances cell survival and proliferation and drives DNA damage and genetic instability. However, higher ROS levels have been found to promote anti-tumorigenic signaling by initiating oxidative stress-induced tumor cell death. Tumor cells develop a mechanism where they adjust to the high ROS by expressing elevated levels of antioxidant proteins to detoxify them while maintaining pro-tumorigenic signaling and resistance to apoptosis. Therefore, ROS manipulation can be a potential target for cancer therapies as cancer cells present an altered redox balance in comparison to their normal counterparts. In this review, we aim to provide an overview of the generation and sources of ROS within tumor cells, ROS-associated signaling pathways, their regulation by antioxidant defense systems, as well as the effect of elevated ROS production in tumor progression. It will provide an insight into how pro- and anti-tumorigenic ROS signaling pathways could be manipulated during the treatment of cancer.

Keywords: mitochondrial ROS; oxidative stress; cancer metabolism; warburg effect; tumor progression; apoptosis; autophagy; NFκB pathway; tumor adaptation; drug resistance; angiogenesis; metastasis; tumor targeting

1. Introduction

Reactive oxygen species (ROS), the partially reduced metabolites of oxygen that possess strong oxidizing capabilities, are deleterious to cells at high concentrations but at low concentrations, they serve complex signaling functions. Reactive oxygen species formed as byproducts of normal cell metabolism are needed for maintaining homeostasis and cellular signaling. Apart from cellular metabolism they are generated by specific plasma membrane oxidases in response to growth factors and cytokines and serve as secondary messengers in specific signaling pathways and play a role in regulating gene expression [1]. Cells have a defense system to maintain ROS at physiologically normal levels, i.e., enzymes called antioxidants, responsible for transforming free radicals into stable, less damaging molecules, the impairment of which may lead to a state of oxidative stress [2]. These oxygen scavenging pathways include conversion of O$_2^-$ to H$_2$O$_2$ by superoxide dismutase (SOD), the action of catalase on H$_2$O$_2$ to produce H$_2$O and O$_2$, decomposition of H$_2$O$_2$ and LOOH by Glutathione peroxidase, and the reduction of H$_2$O$_2$...
by Thioredoxin reduction cycle to produce H$_2$O and also the exogenous detoxification of glutathione transferase [3]. Cancer cells are highly metabolically active and hypoxic cells, and due to massive growth and insufficient vascular irrigation tend to produce increased ROS, which damages DNA by diffusing through the mitochondrial membrane while also acting as signal-transducing messengers in many redox-sensitive molecular pathways involved in cell survival, therapeutic resistance, and progression [3]. Oxidative stress plays a major role in cancer hallmarks like angiogenesis, invasiveness, stemness, and metastatic ability, and hence, reducing oxidative stress with powerful antioxidants has been used as an important strategy for cancer prevention. Additionally, cancer cells develop mechanisms of keeping the increased oxidative stress in check. Therefore, some cancer therapeutic strategies also work by disrupting this check and making the cancer cells susceptible to apoptosis.

2. Source of Reactive Oxygen Species in Cancer Cells

2.1. Mitochondrial ROS

Mitochondria is one of the most prominent sources of reactive oxygen species within a cell which contribute to oxidative stress [4]. The electron transport chain located on the inner mitochondrial membrane generates the majority of mitochondrial ROS during the process of oxidative phosphorylation (OXPHOS). Leakage of electrons at complex I and complex III from ETC leads to a partial reduction of oxygen to form superoxide which undergoes spontaneous dismutation to hydrogen peroxide, both of which are collectively considered as mitochondrial ROS [5]. Endogenous modulators such as NO and Ca$^{2+}$ have been observed to regulate the production of mtROS by regulating the metabolic states of mitochondria. The mitochondrial Ca$^{2+}$ levels increase the rate of electron flow in the ETC and thus decrease mtROS generation [6]. However mitochondrial Ca$^{2+}$ overload increases mtROS production [7]. STAT3, a transcription factor that regulates gene expression in response to cytokines interleukin (IL)-6 and IL-10, also modulates the activity of the ETC [8,9]. Hence a decrease in expression of STAT3 may be correlated to increasing mtROS at complex I [8]. TNF-α that causes the shedding of TNF-α receptor-1 reducing the severity of microvascular inflammation, has been found to induce a calcium-dependent increase in mt ROS [10]. Studies have shown that many ROS-producing enzymes, like NADPH oxidase, xanthine oxidase, and uncoupled eNOS, can stimulate mtROS production in a process called “ROS-induced ROS” [11–13]. Another transcription factor hypoxia-inducible factor 1α (HIF-1α) also plays a prominent role in bringing about a reduction in ROS by a number of mechanisms including induction of pyruvate dehydrogenase kinase 1 (PKD1), which shunts pyruvate away from the mitochondria; triggering mitochondrial selective autophagy; and induction of microRNA-210 blocking OXPHOS [14]. Low levels of mtROS regulate the stability of HIF-1α leading to hypoxia adaptation while moderate levels of mtROS have been found to regulate the production of proinflammatory cytokines by directly activating the inflammasome and mitogen-activated protein kinase (MAPK). However, high levels of mtROS are capable of inducing apoptosis by oxidation of the mitochondrial pores and autophagy by the oxidation of autophagy-specific gene 4 (ATG4) [5]. Depending on the tumor cell microenvironment, the c-Myc gene controls apoptosis by inducing aerobic glycolysis and/or OXPHOS which is required for the activation of certain tumor suppressor proteins, such as Bax and Bak [15–17].

Mitochondria also play an important role in the loss of caveolin 1 (cav-1) in the tumor-associated fibroblast compartment, which is related to the early tumor recurrence, metastasis, tamoxifen-resistance, and aggravated increase in tumor growth [2]. Cav-1 loss induces autophagy and mitophagy, [18] driving the “Reverse Warburg Effect” by a feed-forward mechanism. This onset of inflammation, autophagy, mitophagy, and aerobic glycolysis in the tumor microenvironment is triggered by activation of the transcription factors NFκB and HIF-1α [19,20]. Mitochondria-generated ROS plays an important role in cell proliferation and quiescence. The pro- or anti-tumorigenic signaling is controlled by a mitochondrial ROS switch of the antioxidant SOD2/MnSOD [21]. Cell proliferation is fa-
vored by decreased SOD2/MnSOD activity resulting in increased $O_2^{-}$ production whereas proliferating cells transit into quiescence when SOD/MnSOD activity increases resulting in increased $H_2O_2$ activity [22]. Inactivation of mitochondrial antioxidant responses like the Thioredoxin reductase (TrxR), which causes reduction of oxidized Trx to produce reduced Trx that reacts with ROS, contributes to increased oxidative stress in cancer cells.

Studies have shown that the cellular redox status is impacted by the recruitment of mitochondria by the expression of hTERT. This observation is supported by the presence of hTERT in the mitochondria and since mitochondrial-dependent apoptosis in target cells can be carried about by introducing hTERT inhibitors [23].

2.2. Role of Warburg Effect in ROS

The increased metabolic requirements of the cancer cells are met by upregulation of glucose transport and metabolism irrespective of oxygen supply [24]. There is also some evidence that cancer cells decrease mitochondrial respiration in the presence of oxygen, which suppresses apoptosis [25]. Under hypoxic conditions, the accelerated metabolism produces ROS in cancer cells that is countered by the increased NADPH which is met by the upregulated glycolysis [26,27]. NADPH is an essential cofactor for replenishing reduced glutathione (GSH) which is a critical antioxidant. Therefore, not only are cancer cells’ multiple urgent requirements catered to but cancer cell oxidative stress is also controlled by the Warburg effect [8]. Tumor cells have been reported to switch between the isoforms of pyruvate kinase, used in the last steps of glycolysis [28]. PKM2 the isoform found in high levels in tumor cells is slower and leads to the accumulation of PEP which in turn activates PPP by feedback inhibition of the glycolytic enzyme triosephosphate isomerase (TPI). This produces more NADPH which reduces ROS and further amplifies the inhibitory effect of PKM2 [26,27]. Therefore ROS and PKM2 form a negative feedback loop to maintain ROS in a tolerable and functional range. The ROS-regulated gene, hypoxia-inducible factors (HIF-1$\alpha$) regulates hypoxia-associated genes, some of which are associated with the Warburg effect and its accompanying pathways and hence, are a target of cancer therapies. PKM2 has been found to be the prolyl hydroxylases (PHDs)-induced coactivator for HIF-1$\alpha$ [8,29]. HIF-1$\alpha$ also regulates the MYC proto-oncogene which produces MYC protein [30] that regulates genes participating in energy generation and cell growth and proliferation. HIF-1$\alpha$ and MYC activate hexokinase 2 (HK-II) and pyruvate dehydrogenase kinase 1 (PDHK1), which inhibits TCA and increases conversion of glucose to lactate [31]. Glucose transporter 1 (GLUT1) and lactate dehydrogenase A (LDHA) are also activated by HIF1 and MYC independently, resulting in increased glucose influx and higher glycolytic rates [13]. Warburg effect increases steady-state ROS condition in cancer cells by producing lactate that is extruded through monocarboxylate transporters to the microenvironment of cancer cells which has no antioxidant properties in contrast to pyruvate, citrate, malate, and oxaloacetate together with the reducing equivalents (NADH,$H^+$) which are antioxidant intermediates. This increased oxidative stress in cancer cells is stopped from reaching cytotoxic levels by some antioxidant effects exerted by hexokinase II (HK II) and NADPH,$H^+$ produced through HMP shunt. Latest studies show tumor cells have the capability to carry about both glycolytic and oxidative phosphorylation (OXPHOS) metabolism which makes them resistant to oxidative stress through enhanced antioxidant response and increased detoxification capacity [32]. The changes related to energy metabolism may be correlated to the expression of certain p53 downstream genes regulated by it, including SCO2, TIGAR, and the p53 inducible gene 3 (PIG3) [33–35].

2.3. NADPH Oxidase, Cox, and Xanthine Oxidase Produce ROS

The NADPH oxidizes NOX catalytic subunit carries about the transfer of electrons from NADPH to the molecular oxygen producing ROS as their primary function [36]. The other oxidases like the mitochondrial electron transport chain produce superoxide ($O_2^{**}$) as a by-product of another oxidative reaction. Furthermore, xanthine dehydrogenase gets converted to xanthine oxidase which is a dysfunctional variant of the parent enzyme which
generates uncoupled eNOS. The kinetics of ROS formation and the nature of the ROS produced are different in the four nonphagocytic NADPH oxidase isoforms. Electrons transfer across the biological membranes through NOX and produce O$_2^-$ which gets rapidly converted to H$_2$O$_2$ [17]. This H$_2$O$_2$ after diffusing across the membrane can affect multiple cellular signaling events. Increased NOX-derived ROS in cancer cells affects two major characteristics of cancer progression, i.e., stimulation of cell survival and genomic instability. H$_2$O$_2$ activates MAPK signaling, neutrophil phagocytosis, apoptosis, cellular senescence, and cell growth. It also plays a significant role in oxygen sensing and under hypoxic conditions, it stimulates the release of hypoxia-inducible factor (HIF-1α) and then vascular endothelial growth factor (VEGF) thus promoting angiogenesis [37].

2.4. ER Stress Leads to ROS

In the endoplasmic reticulum, the catalytic processes of oxidoreductase Ero1 and NADPH oxidase (NOX) produce ROS. The major source of cellular ROS is the oxidative protein folding carried about by Ero1 which uses the oxidative power of molecular oxygen to initiate redox relays which ultimately leads to disulfide bond formation in the newly folded proteins. The luminal H$_2$O$_2$ arising from Ero1 and NOX are scavenged by ER peroxidases, such as peroxiredoxin 4 (Prx4), as well as the glutathione peroxidases GPx7 and GPx8 and thereby prevent H$_2$O$_2$ leakage from the ER [38]. The accumulation of unfolded proteins, i.e., persistent ER stress leads to redox-amplified imbalances in the Ero1/PDI electron flow increasing production of ROS at the ER which can be counteracted by an influx of reduced glutathione (GSH) [39]. The production of ROS activates the unfolded protein response (UPR) inactivating the sulfhydration of protein tyrosine phosphatase 1B (PTP1B). This results in increased phosphorylation of PKR-like endoplasmic reticulum kinase (PERK) thereby activating it. PERK plays an important role in restoring cellular homeostasis by regulating a switching mechanism between autophagy and apoptosis [40]. ROS-mediated ER stress also signals activation of Nrf2 antioxidant response, thereby increasing stress resistance and lifespan [41,42]. ROS can leak through the ER through the aquaporin 8, the ER ROS pore. Similarly, Peroxisomal ROS production can leak into the cytosol, and lead to oxidation of important signaling molecules like the NF-kB and PTEN (Figure 1).

![Figure 1. Major intracellular Sources of ROS-mitochondria, peroxisome, endoplasmic reticulum (ER) stress, nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) oxidase, metabolizing enzymes, and extracellular (Radiations, Xenobiotics) sources of reactive oxygen species (ROS) generation. ROS involved in cancer resulting in the development and progression of the disease.](image-url)
3. Mechanism of Oxidative Stress-Related Carcinogenesis

ROS provokes programmed cell death in normal cells. ROS levels may also activate redox-sensitive transcription factors that enhance tumor formation like the Forkhead box class O (FoxO) transcription factors which are activated in response to increased ROS levels and translocated into the nucleus through the cJun N-terminal kinase-dependent signaling pathway. FoxO activation leads to the expression of cellular proteins that serve as ROS scavengers and also regulate a wide variety of additional cellular functions, such as proliferation, apoptosis, and differentiation, that may promote tumorigenesis and cancer progression [43]. It is also possible that through FoxO3, increased ROS levels, induced during chronic inflammation, promote aberrant self-renewal in tumor cells. Tumor cells express catalase in surplus and produce huge concentrations of H\textsubscript{2}O\textsubscript{2}. In this way, the tumor clone itself escapes the toxic action of H\textsubscript{2}O\textsubscript{2} and destroys neighboring healthy cells [44]. We have discussed below, how ROS increases tumorigenesis by a variety of mechanisms: inducing DNA damage, inflammation, evading immune response, regulating signaling pathways controlling autophagy and apoptosis, angiogenesis, and drug resistance.

3.1. Role of ROS in Tumor Cell Proliferation, Survival and Tumor Progression

Increased ROS is responsible for the oxidation of negative feedback loop controllers and hence control the actions of other signaling pathways in tumor growth and programmed cell death by the phosphoinositide 3-kinase/protein kinase B (PI3K/PKB) and mitogen-activated protein kinase (MAPK) signaling pathways [45,46] (Figure 2). Reactive oxygen species generation in cancer cells leads to the inactivation of PTEN that leads to an increase in PI3K/Akt signaling that promotes proliferation. Moreover, the cancer cell cycle progression is promoted when ROS inhibits phosphatase Cdc14B resulting in the activation of cyclin-dependent kinase 1 (Cdk1). As mentioned earlier, the major ROS-regulated gene HIF activates PDK1 that further activates Akt which inhibits the tuberous sclerosis complex (TSC). This downregulates mTOR which is a major regulator of cell growth by controlling mRNA translation, ribosome biogenesis, autophagy, and metabolism [44,47]. MAPK/ERK1/2 are activated by growth factors and K-Ras stimulated pathways, lead to increased cellular proliferation in cancer cells [48]. H\textsubscript{2}O\textsubscript{2} has also been found to be responsible for the activation of ERK1/2 and pro-survival PI3K/Akt signaling pathway, resulting in increased proliferation [49,50]. Studies on breast, leukemia, melanoma, and ovarian cancer have shown ERK1/2 plays additional roles like cell survival, anchorage-independent growth, and motility [51]. The Akt pathway inactivates pro-apoptotic Bad, Bax, Bim, and Foxo transcription factors by phosphorylation thereby promoting cell survival [52,53]. Akt is activated by the Epithelial growth factor (EGF)-derived H\textsubscript{2}O\textsubscript{2} production, observed in ovarian cancers [54]. Cell survival is promoted by the oxidation and inactivation of the negative regulators of PI3K/Akt signaling, i.e., the phosphatases PTEN and PTP1B. The tumor suppressor PTEN has been found to be reversibly inactivated by H\textsubscript{2}O\textsubscript{2} in a variety of cancers [55,56].

PKD signaling plays an important role in the detoxification from elevated ROS production and stimulation of anti-apoptotic genes [57–59]. PKD1 signaling leads to upregulation of NFkB which also plays an important role in the proliferation and survival of the cell. PKD1 also promotes cell survival through activation of ERK1/2 and down-regulation of the pro-apoptotic c-Jun N terminal protein kinase (JNK) pathway [60]. An increase in antioxidants SOD2 and Nrf2 has been observed, however, catalase levels appear to decrease providing a role for PKD1 in cell survival [61]. Other members of the PKD family, PKD2 and PKD3 are implicated to play a role in various other cancers [60]. The tumor suppressor genes produce proteins that play important roles as antioxidants. For instance, p53 could regulate the expression of various antioxidant enzymes including catalase, SOD2, and GPX1 thereby decreasing ROS accumulation [62]. However, since p53 is lost or mutated in most cancers, ROS accumulation and pro-tumorigenic signaling is found.
Figure 2. ROS Drive Mitogenic Signaling Cascades. Increased ROS levels contribute to sustained cell survival and proliferation through many pathways including PI3K/AKT, MAPK/ERK1/2, and PKD. ROS also inactivate their downstream targets including Bad, Bax, Bim, Foxo, and PTEN and the JNK pathway.

3.2. Role of ROS in Apoptosis-Tumor Suppressive Role

Though ROS activates mitogenic signaling pathways, high levels of ROS have the ability to induce cell cycle arrest, senescence, and cancer cell death either by the initiation of intrinsic apoptotic signaling in the mitochondria or by extrinsic apoptotic signaling by the death receptor pathways [63]. ROS induces apoptosis by activating ASK1/JNK and ASK1/p38 signaling pathways in human cancer cells [64,65]. These pathways are activated when TRX1 is oxidized by H$_2$O$_2$ which subsequently dissociates from ASK1, thereby activating the downstream MAP kinase kinase (MKK)4/MKK7/JNK and MKK3/MKK6/p38 pathways leading to suppression of anti-apoptotic factors [17,66–68]. It has also been shown that ROS mediate the downregulation of FLICE inhibitory proteins (FLIP proteins) by ubiquitination and subsequent degradation by the proteasome and thereby induce apoptosis by Fas ligand activation [69]. Collectively, these observations support a tumor-suppressive role of ROS [70]. Recent studies have shown that p53 plays an important role in oxidative stress-related cell death. A regulatory signaling protein of phosphatidyl-3-OH kinase (PI (3) K), p85, participates in the cell death induced by oxidative stress independent of PI (3) K [71]. This protein p85 is upregulated by p53. Sir2α has been found to interact with p53 and attenuate p53-mediated functions and hence is a potential cancer therapeutic target [72].

JNK pathway activation by elevated ROS production results in apoptosis initiated by intrinsic apoptotic signaling through mitochondria or extrinsic apoptotic signaling mediated by death receptor pathways [73–75]. JNK pathway mutations have been found to be inactivated in various cancers suggesting that these pathways may be implicated in apoptotic signaling [76]. The activity of apoptotic effectors including the Bcl-2 family of proteins and cytochrome c are affected by the overproduction of ROS leading to the activation of the caspases, a prominent hallmark of apoptosis, resulting in the cleavage of poly ADP ribose polymerase (PARP), DNA fragmentation, and cell death [77].

As mentioned in Figure 3, elevated ROS can also result in apoptosis by binding of ligands to death receptors which trigger caspase activation of the initiator caspase 8
leading to cleavage of downstream caspase 3 and Bcl-2 protein Bid to tBid which then translocate into the mitochondria causing the release and translocation of cytochrome c [78,79]. Cytochrome c forms a complex with apoptotic protein-activating factor 1 (Apaf-1) and pro-caspase 9 inducing the cleavage of downstream caspase-3 and -7. Members of the Bcl-2 family, anti-apoptotic (Bcl-2, Bcl-w, and Bcl-xL) are inhibited, and pro-apoptotic (Bad, Bak, Bax, Bid, and Bim) are activated in apoptotic signaling [80]. The loss of cytochrome c from the mitochondria will disrupt and damage the mitochondrial ETC and further cause elevated production of ROS [81]. ROS-induced apoptosis can be attributed mainly to decreased GSH levels and the loss of redox homeostasis [82].

3.3. Role of ROS in Autophagy-Both Tumor Suppressive and Tumor Promoting Roles

Autophagy is the controlled lysosomal pathway that regulates cellular homeostasis by degradation and recycling of proteins and organelles within a cell [83]. ROS regulates autophagy in both direct and indirect ways. Direct regulation involves modification of key proteins like Atg4, Atg5, and Beclin which are involved in the autophagy process. Indirect regulation by ROS involves alteration of signaling pathways that can induce autophagy such as the JNK, p38. ROS have also been found to inhibit Akt signaling and downstream mTOR and thereby induce autophagy [84]. Autophagy is one of the first defenses against oxidative stress damage and is upregulated in response to elevated ROS levels [85]. Autophagy has been found to be regulated by the mammalian target of rapamycin complex1 (mTORC1) and its upstream activators PI3K and AKT that suppress autophagy whereas negative regulator of PI3K and AKT pathways PTEN has been found

Figure 3. Role of ROS in apoptosis. Toxic ROS levels damage the mitochondrial membrane releasing cytochrome c to the cytoplasm which forms a complex with Apaf-1 and pro-caspase 9. This induces the cleavage of caspase-3 and -7 resulting in apoptosis. Additionally, binding of TNFα ligand to TNFR1 death receptor triggers the activation of caspase 8 leading to cleavage of caspase 3. Caspase 8 activation also cleaves Bcl-1 protein Bid to form tBid which further leads to the release of cytochrome c in the intrinsic apoptotic pathway.
Antioxidants 2021, 10, x FOR PEER REVIEW 9 of 29

Studies have proven that elevated ROS levels can also lead to defective autophagy. Deletion of autophagy genes ATG5 or ATG7 leads to autophagy inhibition and accumulation of damaged mitochondria which results in chronic oxidative stress, tissue damage, and inflammation which all favor tumor initiation [97–99]. BECLIN1 (ATG6/BECN1) which is an essential gene in autophagy as well as a tumor suppressor has been found deleted in various cancers, resulting in damage to mitochondria, oxidative stress, and disease progression [100–102]. Furthermore, during later stages of tumor initiation, autophagy is required for cell transformation by the RAS oncogene in order to promote cell tolerance to stress, therefore for Ras-induced tumorigenesis, active autophagy is necessary to maintain cellular homeostasis [83].

Figure 4. ROS levels regulate autophagy levels by different pathways: firstly, oxidation of ATG4 leads to accumulation of autophagosomes, secondly, the AMPK signaling cascade induces autophagy through the ULK1 complex. Thirdly, the disruption of BCl-2-BECLIN interactions also initiates autophagy. Lastly, the alteration of mitochondria homeostasis leads to mitophagy activation which checks ROS accumulation by elimination of damaged mitochondria. The degradation of KEAP1 by selective autophagy mediated by p62 leads to the expression of Nrf2-regulated antioxidant genes thereby reducing ROS.

Deregulated autophagy has been found to have a role both in tumor progression and tumor suppression. During the early steps of cancer development, autophagy inhibits tumorigenesis by preventing ROS-induced damages on DNA and protein. However, during the later stages of cancer development (promotion, progression, and metastasis), autophagy plays a pro-tumoral role by eliminating ROS-induced metabolic stress and producing nutrients required for cancer cell survival. The cancer cells under hypoxia induce the formation of ROS which can activate autophagy in neighboring stroma cells which then provide high-energetic nutrients, such as lactate or ketones, necessary for cancer

Figure 4. ROS levels regulate autophagy levels by different pathways: firstly, oxidation of ATG4 leads to accumulation of autophagosomes, secondly, the AMPK signaling cascade induces autophagy through the ULK1 complex. Thirdly, the disruption of BCl-2-BECLIN interactions also initiates autophagy. Lastly, the alteration of mitochondria homeostasis leads to mitophagy activation which checks ROS accumulation by elimination of damaged mitochondria. The degradation of KEAP1 by selective autophagy mediated by p62 leads to the expression of Nrf2-regulated antioxidant genes thereby reducing ROS.

Deregulated autophagy has been found to have a role both in tumor progression and tumor suppression. During the early steps of cancer development, autophagy inhibits tumorigenesis by preventing ROS-induced damages on DNA and protein. However, during the later stages of cancer development (promotion, progression, and metastasis), autophagy plays a pro-tumoral role by eliminating ROS-induced metabolic stress and producing nutrients required for cancer cell survival. The cancer cells under hypoxia induce the formation of ROS which can activate autophagy in neighboring stroma cells which then provide high-energetic nutrients, such as lactate or ketones, necessary for cancer
cell survival and proliferation in accordance with what we have seen earlier, also termed as “tumor-stromal co-evolution”.

Increased ROS production induces autophagy of damaged mitochondria called mitophagy restoring the physiological ROS levels. [88] This selective autophagy is mediated by two different molecular pathways: NIX/BNIP3L and PARKIN (PARK2)/PTEN induced putative kinase 1 (PINK1) [89–92]. Nix/BNIP3L targets mitochondria for degradation after interacting with GABARAP and GABARAPL1 at the autophagosome [93,94]. Whereas selective degradation of damaged dysfunctional mitochondria occurs through PARKIN/PINK1 after ROS induces mitochondrial membrane depolarization [92]. Moreover, Nrf2/Keap1 and SQSTM1/p62 pathways also regulate mitophagy by decreasing ROS [95]. SQSTM1/p62 interacts with Nrf2/Keap1, forming a complex with Keap1, preventing Nrf2 degradation resulting in the release and translocation of Nrf2 to the nucleus where it activates antioxidants [96,97].

Studies have proven that elevated ROS levels can also lead to defective autophagy. Deletion of autophagy genes ATG5 or ATG7 leads to autophagy inhibition and accumulation of damaged mitochondria which results in chronic oxidative stress, tissue damage, and inflammation which all favor tumor initiation [97–99]. BECLIN1 (ATG6/BECN1) which is an essential gene in autophagy as well as a tumor suppressor has been found deleted in various cancers, resulting in damage to mitochondria, oxidative stress, and disease progression [100–102]. Furthermore, during later stages of tumor initiation, autophagy is required for cell transformation by the RAS oncogene in order to promote cell tolerance to stress, therefore for Ras-induced tumorigenesis, active autophagy is necessary to maintain cellular homeostasis [83].

3.4. ROS and Inflammation

The dynamic role of chronic inflammation in cancer has long been established. The presence of inflammatory cells in the cancer cell’s environment enhances their proliferation potential as it is abundant in ROS and RNS promoting DNA damage, upregulation of growth factors and cytokines, and growth-supporting genes along with inactivation of apoptosis [103]. Inflammatory cells further produce more ROS/RNS by inducing oxidant-generating enzymes such as NADPH oxidase, iNOS, xanthine oxidase (XO), and myeloperoxidase (MPO) which further add to the mutation load by damage to DNA, RNA, Lipids, and nitration and oxidation of proteins [1,104]. Inflammatory tissues also release cytokines that activate NFκB, which stimulates COX2, lipoxygenase (LOX), and iNOS, resulting in overproduction of ROS and RNS [104]. These in turn stimulate oncogenes such as c-Jun and c-Fos, the overexpression of which is associated with many cancers. Inflammation promotes cancer initiation and progression via vascularization and remodeling of TME, which is an essential step in tumor cell survival.

As seen earlier, an increase in mitochondrial ROS leads to apoptosis by the TNF-initiated death signal after activating JNK and induction of mitochondrial outer-membrane permeabilization [105,106]. It has been found that O₂•− generates H₂O₂ after reacting with manganese SOD (MnSOD) in the mitochondrial matrix, which activates redox-sensitive transcription factors such as HIF-1α and NFκB and pro-inflammatory cytokines, as well as inflammasomes [107]. These complexes work by activating inflammatory caspases (caspase-1 and -12) and cytokines (IL-1β and IL-18) in macrophages [108]. An increase in ROS inside the cell by NADPH oxidase or mitochondrial ETC causes the redox-sensitive protein thioredoxin (Trx)-binding protein-2 (TBP-2) or TXINP (thioredoxin Interacting protein) to dissociate from Trx enabling the binding of TXINP and NLRP3. NLRP3, a redox-sensitive inflammasome gets activated on interacting with another due to increased intracellular ROS generation [109]. This NLRP3 Inflammasome then leads to activation of caspase-1 and IL-1β and IL-18. MtROS activate TNF-α-converting enzymes which cleave receptor–1 (TNFR1) which is important for inflammatory progression [110]. NADPH oxidase NOX4 also enables ROS generation in response to Inflammatory stimuli LPS, TNF α, hyperoxia, TGF-β, and hypoxia [111]. ASK1 and ASK2 have been found to play a role in
ROS-mediated carcinogenesis via MAPK signaling cascades by induction of inflammation and apoptosis [112].

Oxidative stress and inflammatory response always reinforce each other in the tumor progression. One of the important promoters of tumor development is chronic inflammation which is majorly caused by Nuclear factor-κB (NFκB) activation [113]. The transcription factor, NFκB, plays important role in proliferation, cell survival, regulation of the cell cycle, and the development of resistance to drug therapies [114,115]. It is a sensitive sensor of oxidative stress and detects H₂O₂ at a low level. ROS-mediated activation of mitogen-activated protein kinases (MAPKs) contributes to the production of inflammatory mediators including pro-inflammatory factors like Tumor-necrosis factor (TNF-α) and interleukin-6, interleukin (IL)-1β, and transforming growth factor (TGF)-β which act as mediators leading to activation of NFκB and thereby suppression of cell death and stimulation of cell proliferation. NF-κB expresses proinflammatory cytokines and chemokines and is responsible for the expression and activity of cyclooxygenase 2 (COX2) [116]. Oxidative stress, the NFκB pathway, and the JAK-STAT pathway work together in cancer progression. Oxidative stress stimulating the NFκB pathway generates more ROS which in turn increases oxidative stress. However, inflammatory mediators block the inflammatory process by stimulating the suppressors of cytokine signaling (SOCS), linked to JAKs, interrupting the JAK-STAT pathway [26,117]. NF-κB, a collection of the Rel family of transcription factors, inhibits apoptosis by upregulating several antiapoptotic genes. Nrf2, a transcription factor, is activated in tumor cells to increase the production of antioxidant proteins to maintain the redox balances in the body. Kelch-like ECH-associated protein 1 (Keap1) negatively regulates Nrf2. It has been shown in studies that the activation of Nrf2 can reduce oxidative stress and inflammatory response as Nrf2 dissociates from Keap-1 after its degradation through the ubiquitin-proteasome pathways and travels to the nucleus to activate the antioxidant response elements (AREs) leading to increased activity of antioxidants including catalase, GPXs, PRXs, and glutathione synthesis [118]. Deregulation of the Nrf2 pathway and mutations in Keap1 has been associated with various cancer.

As seen earlier, the hypoxic microenvironment of cancer cells induces autophagy via increased ROS production and subsequent JNK activation. NF-κB downregulates JNK activation by suppression of TNF-α-induced ROS accumulation [119]. The apoptosis in cancer cells is prevented by NFκB activation by upregulating the expression of anti-apoptotic genes, such as those encoding Bcl-XL (B-cell lymphoma XL), BFL1 (a Bcl-2-related protein), and GADD45β (growth arrest and DNA-damage-inducible 45β). ROS have therefore been shown to act as immunosuppressive agents in cancer microenvironments facilitating tumor invasion and metastasis acting not only as oxidative stress mediators but also immune regulators in cancer development.

3.5. ROS and DNA Damage

Significant studies have shown that ROS interacts with cellular macromolecules such as DNA, proteins, and lipids interfering with vital cellular functions. ROS causes oxidative modifications such as DNA base alterations, strand breaks, damage to tumor suppressor genes, and expression of proto-oncogenes resulting in the transformation of normal cells into malignant cells. One of the most abundant oxidative DNA lesions produced is 8-hydroxydeoxy guanosine (8-OHdG), which is mutagenic [120] and is found elevated in various human cancers. The transcription factor Nrf2 controls the expression of antioxidant enzyme genes and also genes that control immune and inflammatory responses, carcinogenesis, and metastasis. It combats oxidative stress by induction of cytoprotective enzymes, such as GST, GPX, and oxidoreductases. Cancer patients exhibit disrupted Nrf2-Keap1 interaction through somatic mutations [121,122]. BRCA1 a tumor suppressor gene found mutated in many cancers, is a caretaker gene, responsible for repairing DNA ultimately helping the cells to cope with oxidative stress [123,124]. It controls the activity of the transcription factors Nrf2 and NFκB and hence can upregulate several genes involved in the antioxidant response. The redox factor 1/AP endonuclease 1 (Ref1/APE1) has also been
found to reduce the generation of ROS in breast cancer cells [125]. Ras activation in tumors has been associated with point mutations and has been observed in 30% of the tumors [126]. The Ras gene family includes G proteins, Ha-ras, N-ras, and Ki-ras, which participate in cell signaling and mutations in this oncogene render the proteins constitutively active [127,128]. Mutant Ras has been found to increase mitochondrial mass and ROS levels leading to DNA damage contributing to transformation [129]. Mutant Ras produces H$_2$O$_2$ by up-regulating the Nox4-p22phox, making Nox4 a critical mediator of oncogenic Ras-induced DNA damage [130]. DNA strand breakage and levels of peroxides have been found to increase significantly with the activation of mutant K-ras in non-transformed epithelial cells. Of the three mitochondrial sirtuins, Sirt3 which belongs to a class of proteins that possess histone deacetylase has been linked to longevity in humans, acting as a tumor suppressor protein [131]. The expression of an oncogene, Myc or Ras, in Sirt3 enhances ROS production by increasing glycolysis and decreasing oxidative phosphorylation. Under hypoxic conditions loss of Sirt3 increases tumorigenesis in cancer cells in a ROS-dependent manner by the activation of by HIF-1α [132]. Oxidative stress and antioxidative stress genes that are considerably altered in tumor cells include-GPX8, ATOX1, PRDX2, PRDX6, PTGS1, SEPP1, and DEFBI2 that are upregulated, while there was a decrease in expression of SIRT2, TTN, CYBA, UCP2, and AKR1B1 [133]. TNF-α may also play an important role in tumor initiation by stimulating the production of intracellular ROS that may damage DNA and lead to genomic mutations [134]. A study exogenously applied ROS-induced G1 arrest in proliferating fibroblasts showing that oxidative stress could play a role in the accumulation of p53 and the activation of cdc2 [135]. Increased ROS levels are associated with the inactivation of certain genes like FoxO3, TP53, and ATM [136]. The tumor suppressor p53 gene TP53 has been found to be significantly and progressively downregulated in cancer cells caused by the excessive oxidation of DNA. The TP53 gene plays an important role in protecting the genome from oxidation by ROS similarly the ataxia telangiectasia mutated (ATM) gene mediates the cellular response to DNA and oxidative damage. The FoxO3 gene decreases ROS levels by influencing the regulation of ATM [24]. Research is being carried out to relate polymorphisms in antioxidant genes to cancer progression as it can lead to altered enzyme activity. Damage to DNA repair enzymes is also associated with an increase in the level of oxidative DNA damage.

3.6. ROS-Mediated Alterations in Protein Stability and Lipid Peroxidation

ROS-mediated cell signaling has been implicated to cause certain protein modifications for instance the sulphydryl (-SH) group of cysteine residues in proteins are modified to their oxidized derivatives, as well as causing changes to occur in the conformation by the formation of intramolecular disulfide bridges which alters the protein activity. However, the impact of protein redox modifications depends on the proteins’ biochemical properties and three-dimensional arrangement, as well as on the abundance and kind of reactive oxygen species (ROS) [137].

The reduced state of critical cysteines in some transcription factors appears to promote DNA binding and transactivation mediated by disulfide-reducing systems (such as thioredoxin) and redox factor-1 (Ref-1) [138]. Intermolecular disulfide linkages can mediate protein dimerization for instance protein kinase (PK) dimerization may lead to its dissociation from an inactive complex. Protein crosslinking can be induced by H$_2$O$_2$ or peroxidase-catalyzed di tyrosine formation [1,134]. A potential mechanism for ROS-mediated alterations in protein stability is by targeting the transitional metal-containing proteins by mixed-function oxidases which target them for ubiquitination and degradation by proteases. ROS attack proteins producing carbonyls and other modifications in several amino acids. These changes on receptors, signal transduction proteins, enzymes, and transporters impair the function of these proteins [139]. Some damage to proteins can be repaired while proteins with irreversible damage are destroyed and replaced with new ones. Lipids are also oxidized by ROS, and this is known as ‘lipid peroxidation’, which results in a reduction in membrane fluidity, an increase in membrane permeability, and
damage to membrane proteins. At low lipid peroxidation, the cells stimulate antioxidants defense systems promoting tumor survival, whereas, under medium or high lipid peroxidation conditions, the cells induce apoptosis or necrosis programmed cell death; both of which cause molecular cell damage facilitating the development of various pathological states [140].

Therefore, lipid peroxidation plays a role in carcinogenesis but its end products such as malondialdehyde, 4-hydroxy-2-nonenal, and isoprostanes, could be used as biomarkers and act as a potential therapeutic strategy in case of colorectal cancer [141]. Oxidized lipids also lead to changes in the physical characteristics of biomembranes at large including bilayer thickness, polarity, and thermal phase behavior. These changes result in augmented permeability, loss of lipid symmetry, and fast lipid trans bilayer diffusion (flip-flop); which further interfere with lipid-protein interactions, leading to changes in metabolic pathways, inflammation, and apoptosis [142].

3.7. Adaptation of Cancer Cells to ROS

Mesenchymal stromal cell (MSC) metabolism has the ability to modify cancer cell metabolism and alter malignancy by transferring mitochondria and/or mitochondrial DNA (mt DNA) to cancer cells thereby increasing mitochondrial content and enhance oxidative phosphorylation (OXPHOS) to favor proliferation and invasion [143]. The stromal metabolism by the cancer-associated fibroblasts produces high-energy nutrients (such as lactate and ketones) that act as fuels for mitochondrial biogenesis [6]. In this way cancer cells maintain a pool of functional mitochondria by coupling mitophagy to mitochondrial biogenesis and also from nonmalignant cells in the tumor microenvironment by forming intercellular tunneling nanotubes (TNTs). Cancer cells follow “tumor-stroma co-evolution” by secreting hydrogen peroxide in adjacent fibroblasts and other stromal cells, which mimics the effects of hypoxia, under aerobic conditions, resulting in excess production of reactive oxygen species (ROS) [6,144]. Therefore, oxidative stress initiated in tumor cells is transferred to cancer-associated fibroblasts laterally and vectorially via Hydrogen peroxide. Excess stromal production of ROS drives the onset of antioxidant defense in adjacent cancer cells, protecting them from apoptosis.

Cancer cells also have mechanisms of immune evasion of ROS through the antioxidant defense. During hypoxia when there is a high production of ROS and NO•, glutathione maintains intracellular redox homeostasis. Glutathione reductase enzyme (GRd) transforms and recycles ROS, by converting the oxidized state of glutathione GSSG to the reduced state GSH, taking electrons from NADPH mainly derived from the pentose phosphate pathway. A decrease in the ratio of GSH to GSSG values is indicative of oxidative stress [145].

Another master regulator of the antioxidant pathway is the transcription factor, Nuclear factor erythroid 2-related factor 2 (Nrf2) which in normal conditions remains bound to its inhibitor Kelch-like ECH-associated protein 1 (Keap1). ROS reacts with redox reactive cysteines in Keap1, releasing Nrf2 into the nucleus where it binds to ARE leading to the expression of genes involved in the cellular antioxidant defense. Inhibition of pro-inflammatory responses of Cox-2 and iNOS expression has been observed with the activation of Nrf2. Nrf2 is inhibited by modifications of cysteine residues of Keap1 and provides cytoprotective effects against Fas-mediated apoptotic pathways [146]. Karyopherin-6 (KPNA6) facilitates nuclear import and attenuates Nrf2 signaling and restores Nrf2 protein to basal levels [147]. Nrf2 impairment leads to oxidative stress, inflammation, and mitochondrial dysfunction [148]. Nrf2 is a tumor suppressor however hyperactivation of Nrf2 creates an environment that favors the survival of both normal and malignant cells, protecting them against oxidative stress [149]. Carbonyl reductase 1 is another important enzyme that regulates the expression of Nrf2 during oxidative stress and helps to detoxify ROS [26].
3.8. Role of ROS in Drug Resistance

The increased ROS production through induction of pro-tumorigenic signaling, enhanced cell proliferation and survival, increased genetic instability and DNA damage, and metabolic adaptations, contribute to drug resistance and hence further progression of cancer. Accumulation of multiple mutations caused by the overproduction of ROS results in an increased risk of tumor cells developing resistance to therapies used. Drug resistance is observed in both AML and CML which is associated with mutations in receptor tyrosine kinases, namely FLT3-ITD and Bcr-Abl. Resistance to the frequently used protein tyrosine kinase inhibitors, midostaurin, and imatinib can be attributed to the DNA oxidation caused by NOX4-generated H$_2$O$_2$ downstream of the pro-survival PI3K/Akt pathway [150,151]. When tumor cells adapt to mitochondrial malfunction it has been found to be linked to drug resistance. To resist chemotheraphy, tumor cells adapt to hypoxia and respiratory injury through the activation of glucose metabolism and therefore become less sensitive to it [152]. Radiation therapy resistance can be attributed to the Hypoxia-induced accumulation of HIF-1$\alpha$ [153–155].

3.9. Role of ROS in Angiogenesis

High levels of reactive oxygen species (ROS) such as superoxide and H$_2$O$_2$ have been found to function as signaling molecules to mediate various growth-related responses including angiogenesis and mutagenesis. Endogenous antioxidant enzymes such as SOD and thioredoxin regulate ROS-dependent angiogenesis. An important angiogenesis growth factor is VEGF that stimulates permeability, proliferation, migration, and tube formation of ECs primarily through the VEGF receptor type2 (VEGFR2, KDR/Flk1) [156,157]. Oxidative stress can increase VEGF expression in tumor cells, which is seen to increase microvessel counts and poor prognosis in cancers [158]. Hypoxia in the tumor microenvironment stimulates the induction of VEGF which stimulates NADPH oxidase. Nox produces ROS which further induces oxidative inactivation of protein tyrosine phosphatases (PTPs) and PTEN to promote VEGFR2 auto phosphorylation activating redox signaling events like c-src, Akt, eNOS, p38MAPK, ERK1/2 [158]. A considerable amount of ROS is generated by NADPH oxidase which includes Nox1, Nox2, Nox4, Nox5, p22phox, p47phox, and the small G-protein Rac1. This oxidase produces ROS which is involved in diverse redox signaling pathways inducing transcription factors and angiogenesis genes. Nox isoforms have been shown to increase in association with ROS production out of which Nox1 is highly overexpressed in human colon cancers and prostate cancers [159]. Nox1-induced H$_2$O$_2$ increases VEGF and VEGFR expression and MMP activity, markers of the angiogenic switch, thereby promoting vascularization and rapid expansion of the tumors [160]. Studies have shown increased expression of Nox4 and Nox5 in melanoma cells and prostate cancer cells respectively [161,162]. Nox1 redox signaling has been found to be controlled by mitochondria and the loss of control of this signaling contributes to tumorigenesis. The redox-sensitive transcription factors HIF-1$\alpha$, p53, Ref1, NFkB, and Ets activate the expression of redox-sensitive genes such as VEGF, MMP, uPA, PAI-1. Trx-1 is a validated cancer drug target that is involved in many of the hallmarks of cancer including increased proliferation, resistance to cell death, and increased angiogenesis [163]. Recent studies have shown that overexpression of a gene SIRT6, through regulating HIF-1$\alpha$, promoted invasion, migration, proliferation, and angiogenesis [164].

3.10. Role of ROS in Metastasis

The effects of ROS are not specific to cancer cells and may result in the destruction of normal cells and tissues as well. These changes in the surroundings of cancer cells bring about invasion and adhesion processes. ROS also serve as second messengers in gene regulatory and signal transduction pathways leading to upregulation of the expression of various genes, including those closely involved in the metastasis and proliferation of cancer cells. Various stages of tumor metastasis need upregulation of matrix metalloproteinases (MMPs), adhesion molecules, EGF, EGF receptor (EGFR), and vascular endothelial growth
factor. ROS have been found to increase the expression and/or activate these proteins, leading to aggravation of tumor metastasis [165]. EGFR, which plays an important role in tumor metastasis is found to be highly expressed in a variety of tumors, such as breast, colon, gastric, pancreatic, ovarian, and prostate cancers, gliomas, and melanomas [166].

The cell’s defense against ROS includes antioxidant enzymes that detoxify ROS and prevent them from accumulating at high concentrations [167]. Cell detachment during metastasis upregulates PDK4 which inhibits PDH and decreases the flux of glucose carbon into the TCA cycle [168]. Cell detachment also upregulates NFkB which increases the expression of MnSOD, the principal mitochondrial antioxidant enzyme, to detoxify mitochondrial ROS resulting from detachment [169]. Moreover, it has been found that cells depleted of MnSOD are hypersensitive to matrix detachment.

Cancer cells follow “tumor-stroma co-evolution” by secreting hydrogen peroxide in adjacent fibroblasts and other stromal cells, which mimics the effects of hypoxia, under aerobic conditions, resulting in excess production of reactive oxygen species (ROS) [6,136]. Therefore, oxidative stress initiated in tumor cells is transferred to cancer-associated fibroblasts laterally and vectorially via Hydrogen peroxide. Excess stromal production of ROS drives the onset of antioxidant defense in adjacent cancer cells, protecting them from apoptosis. When cancer cells metastasize, they detach from the extracellular matrix which activates pro-apoptotic proteins (e.g., BMF, BIM, and BID) and pro-apoptotic members of the Bcl-2 family of proteins (BAK and BAX), eventually resulting in anoikis, a type of apoptotic cell [170]. Cancer cells increase their metastatic potential by elevating their threshold for anoikis. Cancer cells also purposefully restrain pyruvate from entry into mitochondrial oxidative metabolism as the ROS produced as byproducts of mitochondrial respiration exhibit anti-metastasis activity [171]. Thus, cancer cells gain increased anoikis resistance and survival advantage for metastasis.

4. Targeting ROS

ROS has both pro-tumorigenic and anti-tumorigenic signaling which can be manipulated in the treatment of cancer to prevent ROS production or to induce tumor cell death (Table 1).

4.1. Targeting Tumor Death by Upregulation of ROS

By increasing the production of ROS levels to toxic levels and exhaustion of the antioxidant system capacity causing programmed cell death, the anti-tumorigenic signaling of ROS can be targeted as a therapy in cancer. Chemotherapy drugs such as anthracyclines, cisplatin, bleomycin, arsenic trioxide increase ROS production resulting in irreparable damage and cell death, and have been used in the treatment of AML, acute lymphoblastic leukemia (ALL), and acute promyelocytic leukemia (APL) [172]. Daunorubicin is an anthracycline that leads to increased activation of sphingomyelinase and ceramide resulting in activation of the JNK pathway leading to apoptosis [173,174]. This is achieved when it reacts with cytochrome p450 reductase [175-177] to form semiquinone radical intermediates in the presence of reduced NADPH which further reduces O2 to form O2− [178-182]. Another widely used anthracycline in the treatment in a broad spectrum of cancers like breast, esophageal carcinomas, endometrial carcinomas, bile duct, pancreatic, gastric, liver, Hodgins and non-Hodgins lymphoma, osteosarcoma, Kaposi’s sarcoma, and soft tissue sarcomas is Doxorubicin [183,184] which works by increasing production of ROS resulting in the activation of the tumor suppressor p53 and ultimately tumor cell death [185-187]. Another drug called Sulindac, an NSAID, which works by elevating ROS production has been used to treat colon and lung cancer. It damages the mitochondrial membrane and hence the tumor cells become more sensitive to H2O2-induced cell death [188].

As mentioned previously, tumor cells adapt to oxidative stress through increased glucose metabolism thereby inhibiting apoptosis through the redox inactivation of cytochrome c [189]. Another approach used in pancreatic and prostate cancer is to use 2-deoxy glucose (2DG) that inhibits glucose causing elevated ROS production leading to cell
death [190–192]. Studies have shown that 7-formyl-10-methylisoellipticine, an isoellipticine derivative, increases mitochondrial ROS production and induces apoptosis in AML cells with no cytotoxic effects to any organs [193]. A number of chemotherapeutic drugs are currently in use that induces autophagy regulated by ROS.

Table 1. List of chemotherapeutic drugs that induce autophagy and/or apoptosis by regulation of ROS [85].

| Drug                        | Target Cancer Type                  | Primary Action                                                                 | Secondary Action                                                                 | Reference |
|-----------------------------|-------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------|
| Arsenic trioxide            | Ovarian cancer                      | Induces beclin-1-independent autophagic pathway, modulating SnoN/SkiL expression | Alters TGFβ signaling via ROS generation                                         | [194]     |
| Artemisinin                 | Cancer cells                        | Weakens the levels of glutathione, Supply extra ferrous ion to elevate ROS levels | Self-amplification of oxidative stress                                           | [195]     |
| Buthionine-sulfoximine      | Cancer cells                        | Deplete intracellular GSH, may affect STAT3 pathway                            | Induce oxidative stress                                                         | [195,196] |
| Chloroquine                 | MCF-7, HT29, U373 cancer cells      | Sensitizes cells to hypoxia, due to increased ROS, incapacity to reduce mitochondrial content | Inhibition of autophagy, increases cell death                                      | [197]     |
| Cisplatin                   | Head and neck cancer                | Enhances ROS levels                                                            | Induce DNA damage                                                               | [198,199] |
| Curcumin                    | Colon cancer cells                  | Induces ROS production, activation of ERK1/2 and p38 MAPK                      | Autophagic cell death                                                           | [200]     |
| Daunorubicin                | Breast cancer                       | Induce ROS, activates the JNK pathway                                          | Lead to apoptosis                                                               | [114,201] |
| Doxorubicin                 | Breast, esophageal carcinomas, endometrial carcinomas, bile duct, pancreatic, gastric, liver cancer | NO synthase inhibition, Generates ROS, activates p53                          | Induces tumor cell death                                                        | [126–128,202] |
| Diphenyleneiodonium         | pancreatic cancer                   | Jak/STAT pathway inhibited, dephosphorylation of AKT/ASK1 pathway              | Decrease ROS, lead to apoptosis                                                  | [203,204] |
| Fullerene C60 (Nano-C60)    | Normal and drug-resistant cancer cells | Activation of Atg5                                                            | Causes autophagy in a ROS-dependent fashion                                       | [205]     |
| Gemcitabine                 | Head and neck cancer, pancreatic cancer | Activate antioxidant agents, suppress Nox4, block ROS-related signaling pathways, inactivate stromal cells | scavenge ROS                                                                     | [198,206] |
| Idarubicin (IDR)            | Breast cancer                       | Induce oxidative DNA damage                                                   | Upregulate expression of death receptor protein FAS, pro-apoptotic protein Bax, decreased expression of anti-apoptotic protein Bcl-2, activating apoptosis | [207]     |
| Itraconazole                | Liver cancer                        | Increase ROS                                                                  |                                                                                  | [208]     |
| Drug                          | Target Cancer Type                  | Primary Action                                                                 | Secondary Action                              | Reference(s)     |
|------------------------------|-------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------|------------------|
| Medroxyprogesterone          | Head and neck cancer                | Induction of 15d-PGJ$_2$-ligand of PPAR$_{\gamma}$, increased ROS               | Induce apoptosis                              | [198,209]        |
| Metformin                    | Pancreatic cancer                   | Increase MnSOD/SOD2 expression, decrease NOX2 and NOX4 protein expression         | Pro-apoptotic effects                          | [210]            |
| OSU-03012                    | Hepatocellular carcinoma            | Inhibit PDK/AKT signaling pathway inducing apoptotic cell death                   | ROS accumulation and subsequent autophagic cell death | [211]            |
| Panitumumab (EGFR antibody)  | EGFR-expressing metastatic colorectal carcinoma | Increase in GSH levels, reduced stability of proteins                           | Redox imbalance induced autophagy             | [212–214]        |
| Proton pump inhibitor, Esomeprazole | Melanoma                             | Mitochondrial dysfunctions, involvement of NADPH oxidase                         | Accumulation of reactive oxygen species (ROS) | [215]            |
| Proscillaridin A (PSD-A)     | Breast cancer colorectal cancer     | ROS generation, Ca$^{2+}$ oscillation                                            | inhibits STAT3 activation, induces apoptosis and autophagy | [216]            |
| Recombinant human HMGB1      | Glioblastoma cells                  | Bind to TLR2 and TLR4, induce NADPH oxidase to produce ROS                        | activate MAPK and NFkB, release Cytokines      | [217]            |
| Resveratrol                  | Colon cancer cells                  | Induce ROS and subsequent cytotoxic autophagy                                   | Caspase-8/Caspase-3-dependent apoptosis        | [218]            |
| Ruthenium (II) complexes     | Cancer cells                        | DNA damage, Induce ROS                                                          | subsequent protective autophagy along with apoptosis | [219]            |
| Suberoylanilide hydroxamic acid (Zolinza, Vorinostat) | Cutaneous T-cell lymphoma, leukemia | Regulate gene expression, Induce ROS                                              | autophagy, prosurvival                         | [220,221]        |
| Sulfurophane                 | Therapy-resistant pancreatic carcinoma cell | Promote mitochondria-derived ROS                                                 | initiate protective autophagy                  | [222,223]        |
| Sulindac                     | Colon and lung cancer               | mitochondrial damage                                                             | elevate ROS production                         | [129]            |
| Tamoxifen                    | MCF-7 breast cancer cells           | Induced ROS, increased expression of Beclin-1                                    | protective autophagy                           | [224]            |
| Temozolomide                 | Malignant gliomas                   | Suppress ROS/ERK-mediated autophagy                                             | Induce apoptosis                               | [225]            |
| Valproic acid                | Glioma cells                        | Mitochondrial ROS activates the ERK1/2 pathway                                    | Autophagic cell death                          | [226]            |
| Vitamin A                    | Testis tumor Leydig cell lines      | Modulate antioxidant enzyme activities                                           | Induce protective autophagy or apoptosis at different doses | [227]            |
| 2 deoxy glucose (2DG)        | pancreatic and prostate cancer      | Disrupt hydroperoxide metabolism, increased glutathione disulfide accumulation, NADP (+)/NADPH ratios | Elevated ROS production leading to cell death | [132,133]        |
| 7-formyl-10-methyisoellipticine | AML                                 | Increase mitochondrial ROS production                                           | Induces apoptosis                              | [134,228]        |
4.2. Targeting Tumor Proliferation by Downregulation of ROS

ROS production in tumor cells can be inhibited in order to suppress pro-tumorigenic signaling, as reduced ROS levels would mean fewer metabolic adaptations and lower levels of DNA damage and genetic instability and therefore decreased cell survival and proliferation. Metformin given to type 2 diabetes patients, is an inhibitor of complex I of the mitochondrial ETC and has also been found to reduce cancer incidence and mortality [229,230]. Metformin shows pro-apoptotic effects by increasing the protein expression of MnSOD/SOD2 and decreased NOX2 and NOX4 protein expression [231]. NOX4 generated ROS production is a potential target in decreasing pro-tumorigenic effects in various cancers which can be suppressed by flavoprotein inhibitor diphenylene iodonium (DPI) resulting in apoptosis via the AKT/apoptosis signal-regulating kinase 1 (ASK1) pathway [232]. Moreover, studies have shown inhibition of the protein tyrosine kinases FLT3-ITD as well as inhibition of p22phox and NOX4 activity in AML cells results in decreased cell survival along with a decrease in DNA damage and genomic instability [233]. Antioxidants have also been thought to reduce ROS production however it is controversial. Few studies on breast cancer have shown that the overexpression of antioxidant SOD3 reduced breast cancer metastasis implicating the use of antioxidants to reduce ROS in cancer therapy [234]. On the other hand, it has also been found that Vitamin A and E and also beta carotene increased the risk of cancer [235,236].

5. Conclusions

It has become increasingly apparent that ROS plays an inevitable role in cancer biology. Increased ROS production has become a well-recognized hallmark of various cancers, and an understanding of the pro-tumorigenic and anti-tumorigenic actions of ROS can help analyze at what levels they can be used in tumor-suppressive roles. We have not only been able to positively correlate reactive oxygen species (ROS), to carcinogenesis and to malignant progression of tumor cells; but have also found ROS to promote cell motility and shape the tumor microenvironment by inducing inflammation/repair and angiogenesis. This is because ROS can transduce, as signaling intermediates, contributing to genomic damage and genetic instability. ROS are essential to numerous cellular processes including apoptosis and cell growth as well as regulation of autophagy. A better understanding of how ROS regulates autophagy, as well as apoptosis, opens up opportunities to develop cancer treatment strategies by either induction or inhibition of ROS depending on individual cancer’s molecular context and its microenvironment. It is now possible to develop selective and effective therapies to target cancer cells by studying the role of elevated ROS production in cancer, ROS-regulated signaling pathways, and identifying specific antioxidants as targets. With more research on the subject, we can hope to devise ways where ROS can function as a weapon to target cancer cells specifically without damaging normal cells. Newer methods could be used to evaluate ROS spatial specificities in order to better infer their regulatory mechanisms and downstream influences on different subcellular organelles. Work can be done to elucidate each oxidative modification on tumor growth, survival, and migration in order to identify cancer-specific redox vulnerabilities which can be exploited to develop cancer therapies. Overall, a better understanding of cancer-specific redox signaling events holds promise in terms of developing tumor-specific cancer therapies without destroying normal cells.

Author Contributions: Conceptualization, D.K. and S.A.; writing—original draft preparation, S.A., D.K., N.K.J., S.K.J., K.K.K., J.R., S.R., B.R.; writing—review and editing, S.A., D.K., N.K.J., S.K.J., K.K.K., J.R., S.R., B.R.; supervision, D.K.; project administration, D.K.; funding acquisition, D.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was partially funded by SERB, DST, Government of India, grant number ECR/2016/001489.

Acknowledgments: We thank our lab members and collaborators for carefully reading the manuscript and contributing valuable inputs for improving the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

2DG 2-deoxyglucose
8-OHdG 8-hydroxydeoxy guanosine
ALL acute lymphoblastic leukemia
APL acute promyelocytic leukemia
Apaf-1 apoptotic protein-activating factor 1
Ask1 apoptosis signal-regulating kinase-1
AREs antioxidant response elements (AREs)
ATM ataxia telangiectasia mutated
Cdk1 cyclin-dependent kinase 1
COX2 cyclooxygenase 2
CSC cancer stem cells
DR death receptor
EGF epidermal growth factor
EGF-R epidermal growth factor-receptor
Erk1/2 extracellular-regulated kinases 1/2
FAD flavin adenine dinucleotide
FLIP FLICE inhibitory protein
FOXO forkhead homeobox type O
GF growth factor
GF-R growth factor receptor
GSH glutathione
GSSG glutathione disulphide
GPX glutathione peroxidase
GST Glutathione S-transferase
GLUT1 Glucose transporter 1
H2O2 hydrogen peroxide
HIF-1 hypoxia-inducible factor-1
HK2 hexokinase 2
JNK c-Jun N-terminal Kinase
KPNA6 Karyopherin-6
Keap1 Kelch-like ECH-associated protein 1
LDHA lactate dehydrogenase A
MAPK mitogen-activated protein kinase
MMP matrix metalloproteinase
MOMP mitochondrial outer-membrane permeabilization
mTORC1 mammalian target of rapamycin complex 1
mROS mitochondrial ROS
Nox NADPH oxidases
Nrf2 Nuclear factor erythroid 2-related factor 2
NFkB nuclear factor κ-B
NOX NADPH oxidase
OXPHOS Oxidative Phosphorylation
PARP poly ADP ribose polymerase
PDK1 phosphoinositide-dependent kinase 1
PDGF platelet-derived growth factor
PDGF-R platelet-derived growth factor-receptor
PEP Phospho enol pyruvate
PERK PKR-like endoplasmic reticulum kinase
PKM2 Pyruvate kinase isozyme M2
PTPs protein tyrosine phosphatases
PTP1B protein tyrosine phosphatase 1B
PINK1 putative kinase 1  
PI3-K phosphatidylinositol 3-kinase  
PKC protein kinase C  
PKD protein kinase D  
PPP Pentose phosphate pathways  
Prdx peroxiredoxin  
PTEN phosphatase and tensin homolog  
ROS reactive oxygen species  
SOD superoxide dismutase  
SOCS suppressors of cytokine signaling  
TGF\(\beta\) transforming growth factor \(\beta\)  
TIMP tissue inhibitor of metalloproteinases  
TNF\(\alpha\) tumor necrosis factor \(\alpha\)  
TP1 triosephosphate isomerase  
TNTs intercellular tunneling nanotubes  
TrxR Thioredoxin reductase  
VEGF vascular epithelial growth factor

References

1. Thannickal, V.J.; Fanburg, B.L. Reactive oxygen species in cell signaling. *Am. J. Physiol. Cell. Mol. Physiol.* 2000, 279, L1005–L1028. [CrossRef]
2. Halliwell, B. Biochemistry of oxidative stress. *Biochem. Soc. Trans.* 2007, 35, 1147–1150. [CrossRef]
3. Vera-Ramirez, L.; Ramirez-Tortosa, M.; Perez-Lopez, P.; Granados-Principal, S.; Battino, M.; Quiles, J.L. Long-term effects of systemic cancer treatment on DNA oxidative damage: The potential for targeted therapies. *Cancer Lett.* 2012, 327, 134–141. [CrossRef] [PubMed]
4. Starkov, A.A. The Role of Mitochondria in Reactive Oxygen Species Metabolism and Signaling. *Ann. N. Y. Acad. Sci.* 2008, 1147, 37–52. [CrossRef] [PubMed]
5. Li, X.; Fang, P.; Mai, J.; Choi, E.T.; Wang, H.; Yang, X.-F. Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. *J. Hematol. Oncol.* 2013, 6, 19. [CrossRef]
6. Robert, F.F. Crosstalk signaling between mitochondrial Ca\(^{2+}\) and ROS. *Front. Biosci.* 2009, 14, 1197–1218. [CrossRef]
7. Peng, T.-I.; Jou, M.-J. Oxidative stress caused by mitochondrial calcium overload. *Ann. N. Y. Acad. Sci.* 2010, 1201, 183–188. [CrossRef]
8. Handy, D.E.; Loscalzo, J. Redox Regulation of Mitochondrial Function. *Antioxid. Redox Signal.* 2012, 16, 1323–1367. [CrossRef] [PubMed]
9. Wegrzyn, J.; Potla, R.; Chwae, Y.-J.; Sepuri, N.B.V.; Zhang, Q.; Koeck, T.; Derecka, M.; Szczepeanek, K.; Szelag, M.; Gornicka, A.; et al. Function of Mitochondrial Stat3 in Cellular Respiration. *Science* 2009, 323, 793–797. [CrossRef]
10. Doughan, A.K.; Harrison, D.G.; Dikalov, S.I. Molecular Mechanisms of Angiotensin II–Mediated Mitochondrial Dysfunction. *Circ. Res.* 2008, 102, 488–496. [CrossRef] [PubMed]
11. Baudry, N.; Laemmel, E.; Vicaut, E. In vivo reactive oxygen species production induced by ischemia in muscle arterioles of mice: Involvement of xanthine oxidase and mitochondria. *Am. J. Physiol. Circ. Physiol.* 2008, 294, H821–H828. [CrossRef] [PubMed]
12. Ceylan-Isik, A.F.; Guo, K.K.; Carlson, E.C.; Privratsky, J.R.; Liao, S.-J.; Cai, L.; Chen, A.F.; Ren, J. Metallothionein Abrogates GTP Cyclohydrolase I Inhibition–Induced Cardiac Contractile and Morphological Defects. *Hypertension* 2009, 53, 1023–1031. [CrossRef] [PubMed]
13. Semenza, G.L. Hypoxia-inducible factor 1: Regulator of mitochondrial metabolism and mediator of ischemic preconditioning. *Biochim. Biophys. Acta (BBA) Bienerg.* 2011, 1813, 1263–1268. [CrossRef]
14. Wise, D.R.; DeBerardinis, R.J.; Mancuso, A.; Sayed, N.; Zhang, X.-Y.; Pfeiffer, H.K.; Nissim, I.; Daikhin, E.; Yudkoff, M.; McMahon, S.B.; et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proc. Natl. Acad. Sci. USA* 2008, 105, 18782–18787. [CrossRef]
15. Gao, P.; Tchernyshyov, I.; Chang, T.-C.; Lee, Y.-S.; Kita, K.; Ochi, T.; Zeller, K.I.; De Marzo, A.M.; Van Eyk, J.E.; Mendell, J.T.; et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nat. Cell Biol.* 2009, 458, 762–765. [CrossRef]
16. Tomiyama, A.; Serizawa, S.; Tachibana, K.; Sakurada, K.; Samejima, H.; Kuchino, Y.; Kitanaka, C. Critical Role for Mitochondrial Oxidative Phosphorylation in the Activation of Tumor Suppressors Bax and Bak. *J. Natl. Cancer Inst.* 2006, 98, 1462–1473. [CrossRef]
17. Martinez-Outschoorn, U.E.; Pavlides, S.; Whitaker-Menezes, D.; Daumer, K.M.; Milliman, J.N.; Chiavarina, B.; Migneco, G.; Wikiewicz, A.K.; Martinez-Cantarin, M.P.; Flomenberg, N.; et al. Tumor cells induce the cancer associated fibroblast phenotype
via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010, 9, 2423-2433. [CrossRef]

19. Outschoorn, U.E.; Lin, Z.; Trimmer, C.; Flomenberg, N.; Wang, C.; Pavlidis, S.; Estell, R.G.; Howell, A.; Sotgia, F.; Lisanti, M.P. Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect. Cell Cycle 2011, 10, 2504-2520. [CrossRef]

20. Martinez-Outschoorn, U.E.; Balliet, R.M.; Rivadeneira, D.B.; Chiavarina, B.; Pavlidis, S.; Wang, C.; Whitaker-Menezes, D.; Daumer, K.M.; Lin, Z.; Witkiewicz, A.K.; et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution. Cell Cycle 2010, 9, 3276-3296. [CrossRef] [PubMed]

21. Sarsour, E.H.; Venkataraman, S.; Kalen, A.L.; Oberley, L.W.; Goswami, P. Manganese superoxide dismutase activity regulates transitions between quiescent and proliferative growth. Aging Cell 2008, 7, 405-417. [CrossRef]

22. Wang, M.; Kirk, J.S.; Venkataraman, S.; Domann, F.E.; Zhang, H.J.; Schafer, F.Q.; Flanagan, S.W.; Weydert, C.J.; Spitz, D.R.; Buettner, G.R.; et al. Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1α and vascular endothelial growth factor. Oncogene 2005, 24, 8154-8166. [CrossRef]

23. Indran, I.R.; Hande, M.P.; Pervaiz, S. Tumor cell redox state and mitochondria at the center of the non-canonical activity of telomerase reverse transcriptase. Mol. Asp. Med. 2010, 31, 21-28. [CrossRef]

24. Chen, X.; Qian, Y.; Wu, S. The Warburg effect: Evolving interpretations of an established concept. Free Radic. Biol. Med. 2015, 79, 253-263. [CrossRef]

25. Ruckenstuhl, C.; Büttner, S.; Carmona-Gutierrez, D.; Eisenberg, T.; Kroemer, G.; Sigrist, S.J.; Fröhlich, K.-U.; Madeo, F. The Warburg Effect Suppresses Oxidative Stress-Induced Apoptosis in a Yeast Model for Cancer. PLoS ONE 2009, 4, e4592. [CrossRef] [PubMed]

26. Anastasiou, D.; Poulogiannis, G.; Asara, J.M.; Boxer, M.B.; Jiang, J.-K.; Shen, M.; Bellinger, G.; Sasaki, A.T.; Locasale, J.W.; Auld, D.S.; et al. Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses. Science 2011, 334, 1278-1283. [CrossRef]

27. Hamanaka, R.B.; Chandel, N.S. Warburg Effect and Redox Balance. Science 2011, 334, 1219-1220. [CrossRef]

28. Sugiyama, T.; Taniguchi, K.; Matsushita, N.; Tajiri, K.; Futamura, M.; Takai, T.; Ako, Y.; Yoshida, K. MiR-133b inhibits growth of human gastric cancer cells by silencing pyruvate kinase muscle-splicer polypyrimidine tract-binding protein 1. Cancer Sci. 2016, 107, 1767-1775. [CrossRef]

29. Luo, W.; Hu, H.; Chang, R.; Zhong, J.; Knabel, M.; O'Meally, R.; Cole, R.N.; Pandey, A.; Semenza, G.L. Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1. Cell 2011, 145, 732-744. [CrossRef]

30. Liu, J.; Levens, D. Making Myc. Curr. Top. Microbiol. Immunol. 2006, 302, 1–32. [CrossRef] [PubMed]

31. Dang, C.V.; Kim, J.-W.; Gao, P.; Yuste, J. The interplay between MYC and HIF in cancer. Nat. Rev. Cancer 2008, 8, 51-56. [CrossRef] [PubMed]

32. Gentric, G.; Mieulet, V.; Mechta-Grigoriou, F. Heterogeneity in Cancer Metabolism: New Concepts in an Old Field. Antioxid. Redox Signal. 2017, 26, 462-485. [CrossRef] [PubMed]

33. Schmidt, M.W. Element Partitioning: The Role of Melt Structure and Composition. Science 2006, 312, 1646-1650. [CrossRef] [PubMed]

34. Won, K.Y.; Lim, S.-J.; Kim, G.Y.; Kim, Y.W.; Han, S.-A.; Song, J.Y.; Lee, D.-K. Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer. Mol. Cell. Proteom. 2013, 12, 3279-3289. [CrossRef] [PubMed]

35. Luo, W.; Hu, H.; Chang, R.; Zhong, J.; Knabel, M.; O'Meally, R.; Cole, R.N.; Pandey, A.; Semenza, G.L. Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1. Cell 2011, 145, 732-744. [CrossRef]

36. Anastasiou, D.; Poulogiannis, G.; Asara, J.M.; Boxer, M.B.; Jiang, J.-K.; Shen, M.; Bellinger, G.; Sasaki, A.T.; Locasale, J.W.; Auld, D.S.; et al. Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses. Science 2011, 334, 1278-1283. [CrossRef]

37. Hamanaka, R.B.; Chandel, N.S. Warburg Effect and Redox Balance. Science 2011, 334, 1219-1220. [CrossRef]

38. Sugiyama, T.; Taniguchi, K.; Matsushita, N.; Tajiri, K.; Futamura, M.; Takai, T.; Ako, Y.; Yoshida, K. MiR-133b inhibits growth of human gastric cancer cells by silencing pyruvate kinase muscle-splicer polypyrimidine tract-binding protein 1. Cancer Sci. 2016, 107, 1767-1775. [CrossRef]

39. Chakravarthi, S.; Bulleid, N.J. Glutathione Is Required to Regulate the Formation of Native Disulfide Bonds within Proteins. Mol. Cell. Proteom. 2013, 12, 3279-3289. [CrossRef] [PubMed]

40. Liu, Z.; Lv, Y.Z.; Zhao, N.; Guan, G.; Wang, J. Protein kinase R-like ER kinase and its role in endoplasmic reticulum stress-decided cell fate. Cell Death Dis. 2015, 6, e1822. [CrossRef]

41. Ma, Q. Role of Nrf2 in Oxidative Stress and Toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 401-426. [CrossRef]

42. Hourihan, J.M.; Mazzeo, L.E.M.; Fernández-Cárdenas, L.P.; Blackwell, T.K. Cysteine Sulfinylation Directs IRE-1 to Activate the SKN-1/Nrf2 Antioxidant Response. Mol. Cell 2016, 63, 553-566. [CrossRef]

43. Essers, M.A.G.; Weiżjen, S.; De Vries-Smits, A.M.M.; Saarloos, I.; De Ruijer, N.D.; Bos, J.L.; Burgering, B.M.T. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J. 2004, 23, 4802-4812. [CrossRef]

44. Takeuchi, H.; Kondo, Y.; Fujisawa, K.; Kanazawa, T.; Aoki, H.; Mills, G.B.; Kondo, S. Synergistic Augmentation of Rapamycin-Induced Autophagy in Malignant Glioma Cells by Phosphatidylinositol 3-Kinase/Protein Kinase B Inhibitors. Cancer Res. 2005, 65, 3336-3346. [CrossRef] [PubMed]
45. Salmeeen, A.; Andersen, J.N.; Myers, M.P.; Meng, T.-C.; Hinks, J.A.; Tonks, N.K.; Barford, D. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nat. Cell Biol. 2003, 423, 769–773. [CrossRef]

46. Allegra, A.; Pioggia, G.; Tonacci, A.; Casciaro, M.; Musolino, C.; Gangemi, S. Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm. Antioxidants 2020, 9, 1037. [CrossRef]

47. Guertin, D.A.; Sabatini, D.M. Defining the Role of mTOR in Cancer. Cancer Cell 2007, 12, 9–22. [CrossRef]

48. Roberts, P.; Der, C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26, 3291–3310. [CrossRef] [PubMed]

49. Irani, K.; Xia, Y.; Zweier, J.L.; Sollott, S.J.; Der, C.J.; Fearon, E.R.; Sundaresan, M.; Finkel, T.; Goldschmidt-Clermont, P.J. Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts. Science 1997, 275, 1649–1652. [CrossRef]

50. Park, S.-A.; Na, H.-K.; Kim, E.-H.; Cha, Y.-N.; Suh, Y.-J. 4-Hydroxysteriol Induces Anchorage-Independent Growth of Human Mammary Epithelial Cells via Activation of IκB Kinase: Potential Role of Reactive Oxygen Species. Cancer Res. 2009, 69, 2416–2424. [CrossRef]

51. Steelman, L.S.; Abrams, S.L.; Whelan, J.; Bertrand, F.E.; Ludwig, D.E.; Bäsecke, J.; Libra, M.; Milella, M.; Tafuri, A.; et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008, 22, 686–707. [CrossRef] [PubMed]

52. Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor. Cell 1999, 96, 857–868. [CrossRef]

53. Limaye, V.; Li, X.; Hahn, C.; Xia, P.; Berndt, M.C.; Vadas, M.A.; Gamble, J.R. Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1–dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 2005, 105, 3169–3177. [CrossRef]

54. Liu, L.-Z.; Hu, X.-W.; Xia, C.; He, J.; Zhou, Q.; Shi, X.; Fang, J.; Jiang, B.-H. Reactive oxygen species regulate epithelial growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic. Biol. Med. 2006, 41, 1521–1533. [CrossRef]

55. Lee, S.-R.; Yang, K.-S.; Kwon, J.; Lee, C.; Jeong, W.; Rhee, S.G. Reversible Inactivation of the Tumor Suppressor PTEN by H2O2. J. Biol. Chem. 2002, 277, 20336–20342. [CrossRef]

56. Wu, H.; Goel, V.; Haluska, F.G. PTEN signaling pathways in melanoma. Oncogene 2003, 22, 3113–3122. [CrossRef] [PubMed]

57. Storz, P.; Döppler, H.; Toker, A. Protein Kinase D Mediates Mitochondrion-to-Nucleus Signaling and Detoxification from Mitochondrial Reactive Oxygen Species. Mol. Cell. Biol. 2005, 25, 8520–8530. [CrossRef] [PubMed]

58. Storz, P.; Toker, A. NF-κB Signaling: An ALternate Pathway for Oxidative Stress Responses. Cell Cycle 2003, 2, 9–10. [CrossRef] [PubMed]

59. Song, J.; Li, J.; Lulla, A.; Evers, B.M.; Chung, D.H. Protein kinase D protects against oxidative stress-induced intestinal epithelial cell injury via Rho/ROK/PKC-delta pathway activation. Am. J. Physiol. Physiol. 2006, 290, C1469–C1476. [CrossRef] [PubMed]

60. Wang, Y.; Schattenberg, J.M.; Rigoli, R.M.; Storz, P.; Czaja, M.J.; Fang, J.; Jiang, B.-H. Reactive oxygen species regulate epithelial growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic. Biol. Med. 2006, 41, 1521–1533. [CrossRef]

61. Liou, G.-Y.; Döppler, H.; DelGiorno, K.E.; Zhang, L.; Leitges, M.; Crawford, H.C.; Murphy, M.P.; Storz, P. Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions. Cell Rep. 2016, 14, 2325–2336. [CrossRef]

62. Kruiswijk, F.; Labuschagne, C.F.; Vousden, K.H. p53 in survival, death and metabolic health: A lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 2015, 16, 393–405. [CrossRef]

63. Ichijo, H.; Nishida, E.; Irie, K.; ten Dijke, P.; Saitoh, M.; Moriguchi, T.; Takagi, M.; Matsumoto, K.; Miyazono, K.; Gotoh, Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275, 90–94. [CrossRef]

64. Matsuzawa, A.; Nishihito, H.; Tobiime, K.; Takeda, K.; Ichijo, H. Physiological Roles of ASK1-Mediated Signal Transduction in Oxidative Stress- and Endoplasmic Reticulum Stress-Induced Apoptosis: Advanced Findings from ASK1 Knockout Mice. Antioxid. Redox Signal. 2002, 4, 415–425. [CrossRef] [PubMed]

65. Moon, D.-O.; Kim, M.-O.; Choi, Y.H.; Hyun, J.W.; Chang, W.Y.; Kim, G.-Y. Butein induces G2/M phase arrest and apoptosis in human hepatoma cancer cells through ROS generation. Cancer Lett. 2010, 288, 204–213. [CrossRef]

66. Saitoh, M.; Nishitoh, H.; Fuji, M.; Takeda, K.; Tobiime, K.; Sawada, Y.; Kawabata, M.; Miyazono, K.; Ichijo, H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998, 17, 2596–2606. [CrossRef]

67. Tobiime, K.; Matsuzawa, A.; Takahashi, T.; Nishihito, H.; Morita, K.; Takeda, K.; Minowa, O.; Miyazono, K.; Noda, T.; Ichijo, H. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001, 2, 222–228. [CrossRef]

68. Wagner, E.F.; Nebreda, Á.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9, 537–549. [CrossRef] [PubMed]

69. Wang, L.; Azad, N.; Kongkaneramit, L.; Chen, F.; Lu, Y.; Jiang, B.-H.; Rojanasakul, Y. The Fas Death Signaling Pathway Connecting Reactive Oxygen Species Generation and FLICE Inhibitory Protein Down-Regulation1. J. Immunol. 2008, 180, 3072–3080. [CrossRef]

70. Chio, I.I.C.; Tuveson, D.A. ROS in Cancer: The Burning Question. Trends Mol. Mol. 2017, 23, 411–429. [CrossRef] [PubMed]

71. Yin, Y.; Terauchi, Y.; Solomon, G.G.; Aizawa, S.; Rangarajan, P.N.; Yazaki, Y.; Kadowaki, T.; Barrett, J.C. Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nat. Cell Biol. 1998, 391, 707–710. [CrossRef]
Antioxidants 2021, 10, 642

72. Luo, J.; Nikolaev, A.Y.; Imai, S.-I.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative Control of p53 by Sir2α Promotes Cell Survival under Stress. Cell 2001, 107, 137–148. [CrossRef]

73. Dhanasekaran, D.N.; Reddy, E.P. JNK signaling in apoptosis. Oncogene 2008, 27, 6245–6251. [CrossRef] [PubMed]

74. Sastre, J.; Pallardó, F.V.; Viña, J. Mitochondrial Oxidative Stress Plays a Key Role in Aging and Apoptosis. RIBMB Life 2000, 49, 427–435. [CrossRef]

75. Carmody, R.; Cotter, T. Signalling apoptosis: A radical approach. Redox Rep. 2001, 6, 77–90. [CrossRef]

76. Role of JNK in Tumor Development—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/12734425/ (accessed on 13 January 2021).

77. Groeger, G.; Quiney, C.; Cotter, T.G. Hydrogen Peroxide as a Cell-Survival Signaling Molecule. Antioxid. Redox Signal. 2009, 11, 2655–2671. [CrossRef]

78. Fulda, S.; Debatin, K.-M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Int. J. Cancer 2010, 126, 681–689. [CrossRef] [PubMed]

79. Yodkeeree, S.; Sung, B.; Limtrakul, P.; Aggarwal, B.B. Zerumbone Enhances TRAIL-Induced Apoptosis through the Induction of Death Receptors in Human Colon Cancer Cells: Evidence for an Essential Role of Reactive Oxygen Species. Cancer Res. 2009, 69, 6581–6589. [CrossRef]

80. Kelekar, A.; Thompson, C.B. Bcl-2-family proteins: The role of the BH3 domain in apoptosis. Trends Cell Biol. 1998, 8, 324–330. [CrossRef]

81. Chen, Q.; Lesniewski, E.J. Depletion of cardiolipin and cytochrome c during ischemia increases hydrogen peroxide production from the electron transport chain. Free Radic. Biol. Med. 2006, 40, 976–982. [CrossRef]

82. Lu, C.; Armstrong, J. Role of calcium and cyclophilin D in the regulation of mitochondrial permeabilization induced by glutathione depletion. Biochem. Biophys. Res. Commun. 2007, 353, 572–577. [CrossRef] [PubMed]

83. Poillet-Perez, L.; Despouy, G.; Delage-Mourroux, R.; Boyer-Guittaut, M. Interplay between ROS and autophagy in cancer cells, and implication in tumor initiation to cancer therapy. Redox Biol. 2015, 4, 184–192. [CrossRef]

84. Bolisetty, S.; Jaimes, E.A. Mitochondria and Reactive Oxygen Species: Physiology and Pathophysiology. Int. J. Mol. Sci. 2013, 14, 6306–6344. [CrossRef]

85. Li, L.; Ishdorj, G.; Gibson, S.B. Reactive oxygen species regulation of autophagy in cancer: Implications for cancer treatment. Free Radic. Biol. Med. 2012, 53, 1399–1410. [CrossRef]

86. Azad, M.B.; Chen, Y.; Gibson, S.B. Regulation of Autophagy by Reactive Oxygen Species (ROS): Implications for Cancer Progression and Treatment. Antioxid. Redox Signal. 2009, 11, 777–790. [CrossRef] [PubMed]

87. Maddocks, O.D.K.; Vousden, K.H. Metabolic regulation by p53. J. Mol. Med. 2009, 87, 1265–1278. [CrossRef] [PubMed]

88. Zhang, J.; Ney, P.A. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ. 2009, 16, 939–946. [CrossRef] [PubMed]

89. Morselli, E.; Galluzzi, L.; Kepp, O.; Vicenio, J.-M.; Criollo, A.; Maituri, M.C.; Kroemer, G. Anti- and pro-tumor functions of autophagy. Biochim. Biophys. Acta (BBA)—Biomembr. 2009, 1793, 1524–1532. [CrossRef]

90. Fulda, S.; Debatin, K.-M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Int. J. Cancer 2010, 126, 681–689. [CrossRef] [PubMed]

91. Fulda, S.; Debatin, K.-M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Int. J. Cancer 2010, 126, 681–689. [CrossRef] [PubMed]

92. Luo, J.; Nikolaev, A.Y.; Imai, S.-I.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative Control of p53 by Sir2α Promotes Cell Survival under Stress. Cell 2001, 107, 137–148. [CrossRef]

93. Takamura, A.; Komatsu, M.; Hara, T.; Sakamoto, A.; Kishi, C.; Waguri, S.; Eishi, Y.; Hino, O.; Tanaka, K.; Mizushima, N. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011, 25, 795–800. [CrossRef]

94. Schweers, R.L.; Zhang, J.; Randall, M.S.; Loyd, M.R.; Li, W.; Dorsey, F.C.; Kundu, M.; Opferman, J.T.; Cleveland, J.L.; Miller, J.L.; et al. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc. Natl. Acad. Sci. USA 2007, 104, 19500–19505. [CrossRef] [PubMed]

95. Komatsu, M.; Kurokawa, H.; Waguri, S.; Taguchi, K.; Kobayashi, A.; Ichimura, Y.; Sou, Y.-S.; Ueno, I.; Sakamoto, A.; Tong, K.I.; et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat. Cell Biol. 2010, 12, 213–223. [CrossRef]

96. Taguchi, K.; Fujikawa, N.; Komatsu, M.; Ishii, T.; Unno, M.; Akaite, T.; Motoshizuki, H.; Yamamoto, M. Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc. Natl. Acad. Sci. USA 2012, 109, 13561–13566. [CrossRef]

97. Takamura, A.; Komatsu, M.; Hara, T.; Sakamoto, A.; Kishi, C.; Waguri, S.; Eishi, Y.; Hino, O.; Tanaka, K.; Mizushima, N. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011, 25, 795–800. [CrossRef]

98. Mathew, R.; Konagura, S.; Beaudoin, B.; Karp, C.M.; Bray, K.; Degenhardt, K.; Chen, G.; Jin, S.; White, E. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007, 21, 1367–1381. [CrossRef] [PubMed]

99. Karantza-Wadsworth, V.; Patel, S.; Kravchuk, O.; Chen, G.; Mathew, R.; Jin, S.; White, E. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 2007, 21, 1621–1635. [CrossRef] [PubMed]

100. Choi, A.M.; Ryter, S.W.; Levine, B. Autophagy in Human Health and Disease. N. Engl. J. Med. 2013, 368, 651–662. [CrossRef]

101. Liang, X.H.; Jackson, S.; Seaman, M.; Brown, K.; Kempkes, B.; Hibshoosh, H.; Levine, B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nat. Cell Biol. 1999, 402, 672–676. [CrossRef] [PubMed]
130. Weyemi, U.; Lagentechevallier, O.; Boufraqech, M.; Prenois, F.; Courtin, F.; Caillou, B.; Talbot, M.R.; Dardalhon, M.; Al Ghuzlan, A.; Bidart, J.-M.; et al. RO5-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. *Oncoogene* 2011, 31, 1117–1129. [CrossRef]

131. Kim, H.-S.; Patel, K.; Muldoon-Jacobs, K.; Bisht, K.S.; Aykin-Burns, N.; Pennington, J.D.; van der Meer, R.; Nguyen, P.; Savage, J.; Owens, K.M.; et al. SIRT3 Is a Mitochondria-Localized Tumor Suppressor Required for Maintenance of Mitochondrial Integrity and Metabolism during Stress. *Cancer Cell* 2010, 17, 41–52. [CrossRef]

132. Bell, E.L.; Emerling, B.M.; Ricoutt, S.J.H.; Guarente, L.P. Sirt3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. *Oncoogene* 2011, 30, 2986–2996. [CrossRef] [PubMed]

133. Hasselbalch, H.C.; Thomassen, M.; Riley, C.H.; Kjaer, L.; Larsen, T.S.; Jensen, M.K.; Bjerrum, O.W.; Kruse, T.A.; Skov, V. Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression. *PLoS ONE* 2014, 9, e112786. [CrossRef] [PubMed]

134. Phaniendra, A.; Jestadi, D.B.; Periyasamy, L. Free Radicals: Properties, Sources, Targets, and Their Implication in Various Diseases. *Indian J. Clin. Biochem.* 2015, 30, 11–26. [CrossRef] [PubMed]

135. Ayala, A.; Muñoz, M.F.; Argüelles, S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. *Oxidative Med. Cell. Longev.* 2014, 2014, 1–31. [CrossRef]

136. Corcoran, A.; Cotter, T.G. Redox regulation of protein kinases. *FEBS J.* 2013, 280, 1944–1965. [CrossRef]

137. Ando, K.; Hirao, S.; Kabe, Y.; Ogura, Y.; Sato, I.; Yamaguchi, Y.; Wada, T.; Handa, H. A new APE1/Ref-1-dependent pathway leading to reduction of NF-κ B and AP-1, and activation of their DNA-binding activity. *Nucleic Acids Res.* 2008, 36, 4327–4336. [CrossRef] [PubMed]

138. Van Muiswinkel, F.L.; Kuiperij, F.L.V.M.A.H.B. The Nrf2-ARE Signalling Pathway: Promising Drug Target to Combat Oxidative Stress in Neurodegenerative Disorders. *Curr. Drug Target CNS Neurol. Disord.* 2010, 10, 537–542. [CrossRef]

139. Cai, F.; Dupertuis, Y.M.; Pichard, C. Role of polyunsaturated fatty acids and lipid peroxidation on colorectal cancer risk and molecular pathology. *FEBS J.* 2013, 280, 2806–2816. [CrossRef] [PubMed]

140. MohammadAlipour, A.; Dumbali, S.P.; Wenzel, P.L. Mitochondrial Transfer and Regulators of Mesenchymal Stromal Cell Function and Therapeutic Efficacy. *Front. Cell Dev. Biol.* 2020, 8, 603292. [CrossRef] [PubMed]

141. Lisanti, M.P.; Martinez-Outschoorn, U.E.; Chiavarina, B.; Pavlides, S.; Whitaker-Menezes, D.; Tsirigos, A.; Witkiewicz, A.K.; Lin, Z.; Balliet, R.M.; Howell, A.; et al. Understanding the “lethal” drivers of tumor-stroma co-evolution. *Cancer Biol. Ther.* 2005, 6, 1306–1313. [CrossRef]

142. Chai, Y.; Ashraf, S.; Rokutan, K.; Johnston, R.; Thomas, J. S-Thiolation of Individual Human Neutrophil Proteins Including Actin and Metabolism during Stress. *Cancer Cell* 2014, 21, 41–52. [CrossRef]

143. Van Muiswinkel, F.L.; Kuiperij, F.L.V.M.A.H.B. The Nrf2-ARE Signalling Pathway: Promising Drug Target to Combat Oxidative Stress in Neurodegenerative Disorders. *Curr. Drug Target CNS Neurol. Disord.* 2005, 4, 267–281. [CrossRef] [PubMed]

144. Xu, R.-H.; Pelicano, H.; Zhou, Y.; Carew, J.S.; Feng, L.; Bhalla, K.N.; Keating, M.J.; Huang, P. Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia. 2004. Available online: www.aacrjournals.org (accessed on 6 January 2021).

145. Itoh, K.; Wakabayashi, N.; Ishii, Y.; Ishii, T.; Igarashi, K.; Engel, J.D.; Yamamoto, M. Keap1 represses nuclear activation of P53 Tumor Suppressor. *Nat. Med.* 2005, 11, 603–609. [CrossRef] [PubMed]

146. Corcoran, A.; Cotter, T.G. Redox regulation of protein kinases. *FEBS J.* 2013, 280, 1944–1965. [CrossRef]

147. Skorski, T. BCR/ABL regulates response to DNA damage: The role in resistance to genotoxic treatment and in genomic instability. *Oncogene* 2002, 21, 8597–8606. [CrossRef]

148. Sun, Z.; Wu, T.; Zhao, F.; Lau, A.; Birch, C.M.; Zhang, N.D. KPNA6 (Importin 7)-Mediated Nuclear Import of Keap1 Represses the antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. *Arch. Biochem. Biophys.* 2005, 432, 56–62. [CrossRef] [PubMed]

149. Ando, K.; Hirao, S.; Kabe, Y.; Ogura, Y.; Sato, I.; Yamaguchi, Y.; Wada, T.; Handa, H. A new APE1/Ref-1-dependent pathway leading to reduction of NF-κ B and AP-1, and activation of their DNA-binding activity. *Nucleic Acids Res.* 2008, 36, 4327–4336. [CrossRef] [PubMed]

150. Skorski, T. BCR/ABL regulates response to DNA damage: The role in resistance to genotoxic treatment and in genomic instability. *Oncogene* 2002, 21, 8597–8606. [CrossRef]

151. Nowicki, M.O.; Falinski, R.; Koptyra, M.; Slupianek, A.; Stoklosa, T.; Gloc, E.; Nieborowska-Skorska, M.; Skorski, T. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species–dependent DNA double-strand breaks. *Blood* 2004, 104, 3746–3753. [CrossRef]

152. Xu, R.-H.; Pelicano, H.; Zhou, Y.; Carew, J.S.; Feng, L.; Bhalla, K.N.; Keating, M.J.; Huang, P. Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia. 2004. Available online: www.aacrjournals.org (accessed on 14 January 2021).

153. Moeller, B.J.; Cao, Y.; Li, C.Y.; Dewhirst, M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors. *Cancer Cell* 2004, 5, 429–441. [CrossRef]
183. Buzdar, A.U.; Marcus, C.; Blumenschein, G.R.; Smith, T.L. Early and delayed clinical cardiotoxicity of doxorubicin. *Cancer* 1985, 55, 2761–2765. [CrossRef]

184. Wang, X.; Han, W.; Yu, Y.; Zhou, J.; Zhang, R. Doxorubicin-induced cardiomyopathy. In *Doxorubicin: Biosynthesis, Clinical Uses and Health Implications*; Nova Science Publishers, Inc.: Hauppauge, NY, USA, 2014; pp. 43–87.

185. Wang, S.; Konorev, E.A.; Kotamraju, S.; Joseph, J.; Kalivendi, S.; Kalyanaraman, B. Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms. *J. Biol. Chem.* 2004, 279, 25533–25543. [CrossRef] [PubMed]

186. Lowe, S.; Bodis, S.; McClatchey, A.; Remington, L.; Ruley, H.; Fisher, D.; Housman, D.; Jacks, T. p53 status and the efficacy of cancer therapy in vivo. *Science* 1994, 266, 807–810. [CrossRef]

187. Lotem, J.; Peled-Kamar, M.; Groner, Y.; Sachs, L. Cellular Oxidative Stress and the Control of Apoptosis by Wild-Type p53, Cytotoxic Compounds, and Cytokines. 1996. Available online: https://www.pnas.org/content/93/17/9166.short (accessed on 14 January 2021).

188. Marchetti, M.; Resnick, L.; Gamliel, E.; Kesaraju, S.; Weissbach, H.; Binninger, D. Sulindac Enhances the Killing of Cancer Cells Exposed to Oxidative Stress. *PLoS ONE* 2009, 4, e5804. [CrossRef]

189. Vaughn, A.E.; Deshmukh, M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. *Nat. Cell Biol.* 2008, 10, 1477–1483. [CrossRef] [PubMed]

190. Ahmad, I.M.; Abdalla, M.Y.; Aykin-Burns, N.; Simons, A.L.; Oberley, L.W.; Domann, F.E.; Spitz, D.R. 2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress. *Free. Radic. Biol. Med.* 2008, 44, 826–834. [CrossRef] [PubMed]

191. Coleman, M.C.; Asbury, C.R.; Daniels, D.; Du, J.; Aykin-Burns, N.; Smith, B.J.; Li, L.; Spitz, D.R.; Cullen, J.J. 2-Deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. *Free. Radic. Biol. Med.* 2008, 44, 322–331. [CrossRef]

192. Aykin-Burns, N.; Ahmad, I.M.; Zhu, Y.; Oberley, L.W.; Spitz, D.R. Increased levels of superoxide and H$_2$O$_2$ mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. *Biochem. J.* 2009, 418, 29–37. [CrossRef]

193. Russell, E.G.; Guo, J.; O’Sullivan, E.C.; O’Driscoll, C.M.; McCarthy, F.O.; Cotter, T.G. 7-formyl-10-methylisoellipticine, a novel signalling mediator. induces mitochondrial reactive oxygen species (ROS) and shows anti-angiogenic activity in mice. *Investig. New Drugs* 2016, 34, 15–23. [CrossRef]

194. Raffoul, F.; Campla, C.; Nanjundan, M. SnO2/Sk1, a TGFβ signaling mediator. *Autophagy* 2010, 6, 955–957. [CrossRef]

195. Luo, Y.; Sun, X.; Huang, L.; Yan, J.; Yu, B.-Y.; Tian, J. Artemisinin-Based Smart Nanomedicines with Self-Supply of Ferrous Ion to Enhance Oxidative Stress for Specific and Efficient Cancer Treatment. *ACS Appl. Mater. Interfaces* 2019, 11, 29490–29497. [CrossRef]

196. Li, Q.; Yin, X.; Wang, W.; Zhan, M.; Zhao, B.; Hou, Z.; Wang, J. The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine. *Onco. Lett.* 2015, 11, 474–480. [CrossRef]

197. Rouschop, K.M.; Ramaekers, C.H.; Schaaf, M.B.; Keulers, T.G.; Savelkouls, K.G.; Lambin, P.; Koritzinsky, M.; Wouters, B.G. Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. *Radiother. Oncol.* 2009, 92, 411–416. [CrossRef]

198. Yen, C.-J.; Hung, C.-H.; Tsai, W.-M.; Cheng, H.-C.; Yang, H.-L.; Lu, Y.-J.; Tsai, K.-L. Effect of Exercise Training on Exercise Tolerance and Level of Oxidative Stress for Head and Neck Cancer Patients Following Chemotherapy. *Front. Oncol.* 2020, 10. [CrossRef]

199. Mirzaei, S.; Mohammad, A.T.; Gholami, M.H.; Hashemi, F.; Zarrabi, A.; Zabolian, A.; Hushmandi, K.; Makvandi, P.; Samec, M.; Liskova, A.; et al. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance. *Pharmacol. Res.* 2021, 167, 105575. [CrossRef] [PubMed]

200. Lee, Y.J.; Kim, N.-Y.; Suh, Y.-A.; Lee, C. Involvement of ROS in Curcumin-induced Autophagic Cell Death. *Korean J. Physiol. Pharmacol.* 2011, 15, 1–7. [CrossRef]

201. Al-Aamri, H.M.; Ku, H.; Irving, H.R.; Tucci, J.; Meehan-Andrews, T.; Bradley, C. Time dependent response of daunorubicin on cancer cells by fullerene C60 nanocrystal. *Biochem. Pharmacol.* 2012, 83, 1195–1207. [CrossRef]

202. Fang, B. Genetic Interactions of STAT3 and Anticancer Drug Development. *Cancers* 2014, 494–525. [CrossRef] [PubMed]

203. Zhang, Q.; Yang, W.; Man, N.; Zheng, F.; Shen, Y.; Sun, K.; Li, Y.; Wen, L.-P. Autophagy-mediated chemosensitization in cancer cells by fullerene C60 nanocrystal. *Autophagy* 2009, 5, 1107–1117. [CrossRef]

204. Asensio-López, M.C.; Soler, F.; Pascual-Figal, D.; Fernández-Belda, F.; Lax, A. Doxorubicin-induced oxidative stress: The protective effect of nicarandil on HL-1 cardiomyocytes. *PLoS ONE* 2017, 12, e0172803. [CrossRef]

205. Doroshov, J.H.; Juhász, A.; Ge, Y.; Holbeck, S.; Lu, J.; Antony, S.; Wu, Y.; Jiang, G.; Roy, K. Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. *Biochem. Pharmacol.* 2009, 418, 29–37. [CrossRef]

206. Zheng, L.; Li, J.; Zong, L.; Chen, X.; Chen, K.; Jiang, Z.; Nan, L.; Li, X.; Li, W.; Shan, T.; et al. Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer. *Oxidative Med. Cell. Longev.* 2016, 2016, 1–9. [CrossRef]

207. Mizutani, H.; Shiga, C.; Imai, M.; Ikemura, K.; Kitamura, Y.; Ohta, K.; Miyazawa, D.; Sakasnshi, M.; Tahira, T.; Maeda, T.; et al. Idarubicin, an Anthracycline, Induces Oxidative DNA Damage in the Presence of Copper (II). *Anticancer Res.* 2020, 40, 5399–5404. [CrossRef] [PubMed]

208. Wang, W.; Dong, X.; Liu, Y.; Ni, B.; Sai, N.; You, L.; Sun, M.; Yao, Y.; Qu, C.; Yin, X.; et al. Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways. *Biomed. Pharmacother.* 2020, 131, 110661. [CrossRef]
209. Khanim, F.L.; Hayden, R.E.; Birtwistle, J.; Lodi, A.; Tiziani, S.; Davies, N.J.; Ride, J.P.; Viant, M.R.; Günther, U.L.; Mountford, J.C.; et al. Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia. *PloS ONE* **2009**, *4*, e8147. [CrossRef] [PubMed]

210. Mogavero, A.; Maiorana, M.V.; Zanutto, S.; Varinelli, L.; Bozzi, F.; Belfiore, A.; Volpi, C.C.; Gloghini, A.; Pierotti, M.A.; Gariboldi, M. Metformin Transiently Inhibits Colorectal Cancer Cell Proliferation as a Result of Either AMPK Activation or Increased ROS Production. *Sci. Rep.* **2017**, *7*, 1–12. [CrossRef] [PubMed]

211. Gao, M.; Yeh, P.Y.; Lu, Y.-S.; Hsu, C.-H.; Chen, K.-F.; Lee, W.-C.; Feng, W.-C.; Chen, C.-S.; Kuo, M.-L.; Cheng, A.-L. OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Species–Related Autophagy in Hepatocellular Carcinoma. *Cancer Res.* **2008**, *68*, 9348–9357. [CrossRef] [PubMed]

212. Giannopoulou, E.; Antonacopoulou, A.; Matsouka, P.; Kalofonos, H.P. Autophagy: Novel action of panitumumab in colon cancer. *Anticancer. Res.* **2009**, *29*, 5077–5082.

213. Peeters, M.; Balfour, J.; Arnold, D. Review Article: Panitumumab A Fully Human Anti-EGFR Monoclonal Antibody for Treatment of Metastatic Colorectal Cancer. *Aliment. Pharmacol. Ther.* **2008**, *26*, 269–281. [CrossRef] [PubMed]

214. Gemmete, J.J.; Mukherji, S.K. Panitumumab (Vectibix). *Am. J. Neuroradiol.* **2011**, *32*, 1002–1003. [CrossRef] [PubMed]

215. Marino, M.; Fais, S.; Djavaherimergny, M.; Villa, A.; Meschini, S.; Lozupone, F.; Venturi, G.M.; Della Mina, P.; Pattingre, S.; Rivoltini, L.; et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. *Cell Death Dis.* **2010**, *1*, e87. [CrossRef]

216. Saleem, M.Z.; Alshwmi, M.; Zhang, H.; Din, S.R.U.; Nisar, M.A.; Khan, M.; Alam, S.; Alam, G.; Jin, L.; Ma, T. Inhibition of JNK-Mediated Autophagy Promotes Proscillaridin A–Induced Apoptosis via ROS Generation, Intracellular Ca++ Oscillation and Inhibiting STAT3 Signaling in Breast Cancer Cells. *Front. Pharmacol.* **2020**, *11*, 1055. [CrossRef]

217. Gdynia, G.; Keith, M.; Kopitz, J.; Bergmann, M.; Fassl, A.; Weber, A.N.; George, J.; Kees, T.; Zentgraf, H.-W.; Westlinder, O.; et al. Danger Signaling Protein HMGB1 Induces a Distinct Form of Cell Death Accompanied by Formation of Giant Mitochondria. *Cancer Res.* **2010**, *70*, 8558–8568. [CrossRef]

218. Li, J.; Liu, R.; Lei, Y.; Wang, K.; Lau, Q.C.; Xie, N.; Zhou, S.; Nie, C.; Chen, L.; Wei, Y.; et al. Proteomic analysis revealed association of dietary sulforaphane act independently of each other and require oxidative stress in pancreatic cancer. *J. Nutr. Biochem.* **2010**, *21*, 714–721. [CrossRef]

219. Miki, H.; Uehara, N.; Kimura, A.; Sasaki, T.; Yori, T.; Yoshizawa, K.; Tsubura, A. Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. *Int. J. Oncol.* **2012**, *40*, 1020–1028. [CrossRef]

220. Xiao, D.; Powolny, A.A.; Antosiewicz, J.; Hahm, E.-R.; Bommareddy, A.; Zeng, Y.; Desai, D.; Amin, S.; Herman-Antosiewicz, A.; Singh, S.V.; Budigner, G.S.; et al. Cellular Responses to Cancer Chemopreventive Agent D,L-Sulforaphane in Human Prostate Cancer Cells Are Initiated by Mitochondrial Reactive Oxygen Species. *Pharm. Res.* **2009**, *26*, 1729–1738. [CrossRef] [PubMed]

221. Fortunato, F.; Naumann, P.; Zentgraf, H.; Büchler, M.W.; Herr, I.; Werner, J. Autophagy and cell death signaling following dietary sulforaphane act independently of each other and require oxidative stress in pancreatic cancer. *Cell Death Dis.* **2010**, *1*, 70. [CrossRef] [PubMed]

222. Perri, M.; Pingitore, A.; Cione, E.; Vilardi, E.; Perrone, V.; Genchi, G. Proliferative and anti-proliferative effects of retinoic acid on metastatic melanoma cells. *Free Radic. Biol. Med.* **2008**, *45*, 369–378. [CrossRef] [PubMed]

223. De Medina, P.; Silvente-Poirot, S.; Poirot, M. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. *Autophagy* **2009**, *5*, 1066–1067. [CrossRef]

224. Lin, C.-J.; Lee, C.-C.; Shih, Y.-L.; Lin, T.-Y.; Wang, S.-H.; Lin, Y.-F.; Shih, C.-M. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. *Front. Pharmacol.* **2019**, *10*, 1–10. [CrossRef] [PubMed]

225. Miller, C.M.; O’sullivan, E.C.; McCarthy, F.O. Novel 11-Substituted Ellipticines as Potent Anticancer Agents with Divergent Activity against Cancer Cells. *Pharmaceuticals* **2019**, *12*, 90. [CrossRef]

226. Wheaton, W.W.; Weinberg, S.E.; Hamanaka, R.B.; Soberanes, S.; Sullivan, L.B.; Anso, E.; Glasauer, A.; Dufour, E.; Mutlu, G.M.; Budigner, G.S.; et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. *eLife* **2014**, *3*, e02242. [CrossRef] [PubMed]

227. Owen, M.R.; Doran, E.; Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. *Biochem. J.* **2000**, *348*, 607–614. [CrossRef]

228. Cheng, G.; Lanza-Jacoby, S. Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: Role of NOX4. *Biochem. Biophys. Res. Commun.* **2015**, *465*, 41–46. [CrossRef]
232. Mochizuki, T.; Furuta, S.; Mitsushita, J.; Shang, W.H.; Ito, M.; Yokoo, Y.; Yamaura, M.; Ishizone, S.; Nakayama, J.; Konagai, A.; et al. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. *Oncogene* 2006, 25, 3699–3707. [CrossRef]

233. Stanicka, J.; Russell, E.G.; Woolley, J.F.; Cotter, T.G. NADPH Oxidase-generated Hydrogen Peroxide Induces DNA Damage in Mutant FLT3-expressing Leukemia Cells. *J. Biol. Chem.* 2015, 290, 9348–9361. [CrossRef] [PubMed]

234. Fitzgerald, M.P.; Zhong, W.; Askeland, R.W.; Domann, F.E. Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasis. *Oncogene* 2014, 33, 358–368. [CrossRef]

235. Omenn, G.S.; Goodman, G.E.; Thornquist, M.D.; Balmes, J.R.; Cullen, M.R.; Glass, A.G.; Keogh, J.P.; Meyskens, F.L.; Valanis, B.G.; Williams, J.H.; et al. Effects of a Combination of Beta Carotene and Vitamin A on Lung Cancer and Cardiovascular Disease. *N. Engl. J. Med.* 1996, 334, 1150–1155. [CrossRef]

236. Kein, E.A.; Thompson, I.M.; Tangen, C.M.; Crowley, J.J.; Lucia, M.S.; Goodman, P.J.; Minasian, L.M.; Ford, L.G.; Parnes, H.L.; Gaziano, J.M.; et al. Vitamin E and the Risk of Prostate Cancer: The selenium and vitamin e cancer prevention trial (SELECT). *JAMA* 2011, 306, 1549–1556. [CrossRef]